Selenium-containing compound and application thereof
By developing a new structure of Selenium-containing small molecule GLP-1R agonist based on Danuglipron, the shortcomings of existing agonists in terms of pharmacokinetic properties and toxicity are solved, and effective GLP-1R agonism and improved metabolic diseases are achieved. The potential of treatment.
Patent Information
- Application Number
- CN202410914694.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-27
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-05
AI Technical Summary
Existing GLP-1R small molecule agonists such as Danuglipron have insufficient pharmacokinetic properties and toxicity, and lack effective oral small molecule agonists, which makes it difficult to treat metabolic diseases by agonizing GLP-1 receptors. demand.
A new structure based on Danuglipron-based small-molecule GLP-1R agonist containing selenium is developed. By optimizing the structure of the compound, it improves pharmacokinetic properties and reduces cardiotoxicity, it provides a compound of general formula for the preparation of orally effective GLP-1R agonist.
Complete agonist effect of GLP-1R-cAMP signaling pathway is achieved, and the compounds have nanomolar half-effect concentrations, significantly improve pharmacokinetic properties and bioavailability, and have the potential to develop for the prevention and treatment of metabolic diseases.
Smart Images

Figure CN118894846A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a selenium-containing compound and a use thereof. Background Art
[0002] As an element of the fourth period and the sixth main group, selenium is rarely used in the field of medicinal chemistry and drug design. However, in recent years, researchers in the field of medicinal chemistry have gradually increased their interest in the application of selenium in drug design, development and synthesis. Selenium has unique oxidation-reduction properties and nucleophilicity due to its larger atomic structure and loose outer valence electron properties. In vivo, selenium-containing molecules usually show higher biological reactivity than sulfur-containing molecules, are easy to form Se-S adducts, and significantly enhance the selective absorption effect of cancer cells. Therefore, selenium-containing molecules are often used as antioxidants, free radical scavengers or pro-oxidants to participate in inflammation suppression therapy or anti-tumor therapy. Selenium atoms are also used as bioisosteres of oxygen atoms in drug molecule design and natural product modification. Many compounds have thus acquired unique drug activity. The introduction or replacement of selenium atoms has also become a new perspective for the strategy of improving the properties of compounds.
[0003] GLP-1 is a fast-metabolizing endogenous incretin hormone, produced from intestinal tissue and central nervous tissue, and acts on GLP-1R. Intestinal GLP-1 is widely distributed in tissues throughout the body along the circulatory system, and mainly plays a role in regulating blood sugar content and metabolism; central GLP-1 plays a neurotransmitter function and inhibits appetite and food intake. Due to its important blood sugar and metabolic regulation functions, GLP-1R agonists have become important drugs for the treatment and control of metabolic diseases such as diabetes. The GLP-1R agonists currently approved for marketing are all peptidomimetic compounds that simulate GLP-1 peptides, such as exenatide, liraglutide, dulaglutide, semaglutide and other GLP-1 analogs. At present, people are still exploring new types and new dosage forms of GLP-1R agonists, including iteratively optimized GLP-1 peptide analogs, orally available peptide agonists, small molecule agonists, allosteric agonists, etc.
[0004] Danuglipron (PF-06882961) is a small molecule direct GLP-1R agonist of the benzimidazole-6-carboxylic acid class developed by Pfizer, which has picomolar GLP-1R-cAMP signaling pathway agonist activity (EC 50 ) and full agonist effect (E max), is a partial agonist of GLP-1R. Structural biology information shows that Danuglipron compounds occupy part of the GLP-1 peptide action site, inducing and simulating the conformation of key ligand-receptor interactions with a structural water network. Danuglipron shows primate species-specific agonism, and oral administration shows acceptable oral absorption and in vivo metabolism. Glucose tolerance tests show that Danuglipron can effectively improve the glucose tolerance level of experimental subjects, promote the release of insulin, and effectively control the blood sugar level of experimental subjects. The Phase II clinical trial of Danuglipron for the indication of blood sugar control has been completed, and Phase III clinical trials are underway.
[0005] There are few reports on small molecule GLP-1R agonists, but as the full-length structure of GLP-1R before binding to the ligand is revealed, the structural types of small molecule GLP-1R agonists will be diversified. The report of Danuglipron molecule provides a template for this type of structural optimization, but its pharmacokinetic properties and toxicity are not ideal. Summary of the invention
[0006] Purpose of the invention: The first purpose of the present invention is to provide a selenium-containing compound; the second purpose of the present invention is to provide uses of the selenium-containing compound, including uses for preparing GLP-1 receptor agonists and for preparing drugs for diseases that are directly or indirectly treated or alleviated by stimulating the GLP-1 receptor.
[0007] The present invention develops a small molecule GLP-1R agonist containing selenium and effective orally based on the new structure of Danuglipron, which is used to prepare drugs for metabolic diseases that can regulate GLP-1R related signals. Compared with peptide drugs, this type of small molecule agonist is effective orally; at the same time, it improves the pharmacokinetic properties and cardiac toxicity of Danuglipron.
[0008] Technical solution: The purpose of the present invention is achieved through the following technical solution:
[0009] The present invention provides a compound of general formula I or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph thereof:
[0010]
[0011]
[0012] in,
[0013] Ring A is selected from C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 5-12 Spirobicyclic, C5-12 Spiroheterobicyclic, C 5-12 Fused bicyclic group, C 5-12 Fused heterobicyclic group, C 5-12 Bridged ring or C 5-12 bridged heterocyclic group;
[0014] L is selected from -C(O)-, -O-, -S-, -CR 4 R 5 or -NR 6 -;
[0015] R 4 , R 5 are each independently selected from hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, -NR 5 a 5 b, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group; the C1-C6 alkyl or C1-C6 alkoxy is optionally substituted by one or more of the following substituents: halogen, oxo, cyano, hydroxyl, C3-C6 saturated or partially saturated cycloalkyl; the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclic group is optionally substituted by one or more of the following substituents: halogen, oxo, cyano or -NR 5 a 5 b;
[0016] R 5 a. R 5 b are each independently selected from hydrogen or C1-C6 alkyl;
[0017] R 6 Selected from hydrogen, C1-C6 alkyl, C3-C10 cycloalkyl, heterocyclic group, -S(O) 2 R 6 a or
[0018] -S(O) 2 N(R 6 a)(NR 6 b); the cycloalkyl or heterocyclic group is optionally substituted by a C1-C6 alkyl, -F or cyano group;
[0019] R 6 a. R 6 b are each independently selected from -H, C1-C6 alkyl or C3-C10 cycloalkyl;
[0020] R 1C1-C6 alkyl substituted with 3-6 membered heterocyclyl, C1-C6 alkyl substituted with C3-C6 cycloalkyl, C1-C6 alkyl substituted with 5-8 membered heteroaryl, C1-C6 alkyl substituted with C1-C6 alkoxy, 3-6 membered heterocyclyl, C3-C6 cycloalkyl or 5-8 membered heteroaryl; the 3-6 membered heterocyclyl, C3-C6 cycloalkyl, 5-8 membered heteroaryl or C1-C6 alkoxy is optionally replaced by one of the following: substituted by one or more substituents: H, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, cyano, cyano-substituted C1-C6 alkyl, hydroxy, hydroxy-substituted C1-C6 alkyl, halo-substituted C1-C6 alkyl, halo-substituted C3-C6 cycloalkyl, halo-substituted C1-C6 alkoxy, halo-substituted C1-C6 alkylamino, acyl, amide, aminoacyl, sulfonyl or amino;
[0021] R 2 Each is independently selected from a hydrogen atom, deuterium, halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C1-C6 alkoxy, amino, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group;
[0022] R 3 Each is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0023] X 1 , X 2 , X 3 and X 4 The same or different, and each independently selected from -CR 7 or N atoms;
[0024] R 7 is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl or heteroaryl;
[0025] G is selected from G1 or G2; the structural formulas of G1 and G2 are as follows:
[0026]
[0027] Ring B and Ring C are each independently selected from a 6-12 membered aryl group or a 6-12 membered heteroaryl group;
[0028] Y and Z are each independently selected from -CH 2 -, -S-, -SO-, -SO 2 -, -(O=S=NH)-, -Se- or -Se(O)-;
[0029] R 8 , R 11 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl being optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0030] R 9 , R 10 , R 12 , R 13 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0031] EE is selected from -COOH or a carboxyl surrogate; the carboxyl surrogate is selected from:
[0032]
[0033] m is 0, 1, 2 or 3;
[0034] n is 0, 1, 2, 3 or 4;
[0035] o is 0, 1, 2, 3, 4, or 5;
[0036] p is 0, 1, 2, 3, 4 or 5.
[0037] The present invention also provides a compound of general formula II or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph thereof:
[0038]
[0039] in,
[0040] Ring A is selected from C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 5-12 Spirobicyclic, C 5-12 Spiroheterobicyclic, C 5-12 Fused bicyclic group, C 5-12 Fused heterobicyclic group, C 5-12 Bridged ring or C 5-12 bridged heterocyclic group;
[0041] L is selected from -C(O)-, -O-, -S-, -CR 4 R 5 or -NR 6 -;
[0042] R 4 , R 5 are each independently selected from hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, -NR 5 a 5 b, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group; the C1-C6 alkyl or C1-C6 alkoxy is optionally substituted by one or more of the following substituents: halogen, oxo, cyano, hydroxyl, C3-C6 saturated or partially saturated cycloalkyl; the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclic group is optionally substituted by one or more of the following substituents: halogen, oxo, cyano or -NR 5 a 5 b;
[0043] R 5 a. R 5 b are each independently selected from hydrogen or C1-C6 alkyl;
[0044] R 6 Selected from hydrogen, C1-C6 alkyl, C3-C10 cycloalkyl, heterocyclic group, -S(O) 2 R 6 a or -S(O) 2 N(R 6 a)(NR 6 b); the cycloalkyl or heterocyclic group is optionally substituted by a C1-C6 alkyl, -F or cyano group;
[0045] R 6 a. R 6 b are each independently selected from -H, C1-C6 alkyl or C3-C10 cycloalkyl;
[0046] R 1C1-C6 alkyl substituted with 3-6 membered heterocyclyl, C1-C6 alkyl substituted with C3-C6 cycloalkyl, C1-C6 alkyl substituted with 5-8 membered heteroaryl, C1-C6 alkyl substituted with C1-C6 alkoxy, 3-6 membered heterocyclyl, C3-C6 cycloalkyl or 5-8 membered heteroaryl; the 3-6 membered heterocyclyl, C3-C6 cycloalkyl, 5-8 membered heteroaryl or C1-C6 alkoxy is optionally replaced by one of the following: substituted by one or more substituents: H, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, cyano, cyano-substituted C1-C6 alkyl, hydroxy, hydroxy-substituted C1-C6 alkyl, halo-substituted C1-C6 alkyl, halo-substituted C3-C6 cycloalkyl, halo-substituted C1-C6 alkoxy, halo-substituted C1-C6 alkylamino, acyl, amide, aminoacyl, sulfonyl or amino;
[0047] R 2 Each is independently selected from a hydrogen atom, deuterium, halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C1-C6 alkoxy, amino, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group;
[0048] R 3 Each is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0049] X 1 , X 2 , X 3 and X 4 The same or different, and each independently selected from -CR 7 or N atoms;
[0050] R 7 is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl or heteroaryl;
[0051] G is selected from G1 or G2; the structural formulas of G1 and G2 are as follows:
[0052]
[0053] Ring B and Ring C are each independently selected from a 6-12 membered aryl group or a 6-12 membered heteroaryl group;
[0054] Y and Z are each independently selected from -CH 2 -, -S-, -SO-, -SO 2 -, -(O=S=NH)-, -Se- or -Se(O)-;
[0055] R 8 , R 11 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl being optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0056] R 9 , R 10 , R 12 , R 13 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0057] R 14 each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0058] EE is selected from -COOH or a carboxyl surrogate; the carboxyl surrogate is selected from:
[0059]
[0060]
[0061] m is 0, 1, 2 or 3;
[0062] n is 0, 1, 2, 3 or 4;
[0063] o is 0, 1, 2, 3, 4, or 5;
[0064] p is 0, 1, 2, 3, 4 or 5;
[0065] q is 0, 1, 2, or 3.
[0066] In certain preferred embodiments,
[0067] Ring A is selected from C 3-8 Cycloalkyl or C 2-9 Heterocyclic group;
[0068] L is selected from -CR 4 R 5 ;
[0069] R 1 Selected from C1-C6 alkyl substituted by 3-6 membered heterocyclyl, C1-C6 alkyl substituted by C3-C6 cycloalkyl, C1-C6 alkyl substituted by 5-8 membered heteroaryl, C1-C6 alkyl substituted by C1-C6 alkoxy;
[0070] EE is selected from -COOH or carboxyl surrogate;
[0071] R 4 , R 5 As defined in Formula I or Formula II.
[0072] In certain preferred embodiments,
[0073] Ring A is selected from C 2-9 Heterocyclic group;
[0074] Y and Z are each independently selected from -Se- or -Se(O)-;
[0075] EE is selected from -COOH,
[0076] The compounds of the general formula I or II of the present invention are preferably the compounds shown in the following Table 1:
[0077] Table 1 Preferred compounds
[0078]
[0079]
[0080] The above-mentioned compounds of general formula I or general formula II of the present invention may also exist in the form of their salts, hydrates, solvates, which are converted into compounds of general formula I or general formula II in vivo. For example, within the scope of the present invention, according to processes known in the art, the compounds of the present invention are converted into the form of pharmaceutically acceptable salts, and they are used in the form of salts.
[0081] Certain compounds of the present invention may exist in multiple crystalline forms.
[0082] All tautomeric forms of the compounds of formula I or II of the present invention are included within the scope of the present invention. The compounds of the present invention may exist in specific geometric or stereoisomer forms. Additional asymmetric carbon atoms may exist in substituents such as alkyl, and all these isomers and their mixtures are included within the scope of the present invention.
[0083] The present invention also provides a pharmaceutical composition, which comprises a compound of Formula I or Formula II or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polycrystal thereof and a pharmaceutically acceptable carrier or excipient.
[0084] The pharmaceutical composition of the present invention can be administered in various known ways, such as orally, parenterally, by inhalation spray or via an implanted reservoir. The pharmaceutical composition of the present invention can be administered alone or in combination with other drugs. Oral compositions can be in any orally acceptable dosage form, including but not limited to tablets, capsules, emulsions, suspensions, dispersions and solutions. Commonly used pharmaceutically acceptable carriers or excipients include stabilizers, diluents, surfactants, lubricants, antioxidants, adhesives, colorants, fillers, emulsifiers, etc.
[0085] Sterile injectable compositions can be formulated using suitable dispersing agents or wetting agents and suspending agents according to techniques known in the art. Pharmaceutically acceptable carriers and solvents that can be used include water, mannitol, sodium chloride solution, and the like.
[0086] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The dosage level selected depends on a variety of factors, including the activity of the specific compound of the present invention or its salt used, the route of administration, the time of administration, the excretion rate of the specific composition used, the duration of treatment, other drugs, compounds and / or materials used in combination with the specific composition used, the age, sex, weight, general health and previous medical history of the patient being treated, and similar factors well known in the medical field.
[0087] The present invention also provides the use of the compound of formula I or formula II or its pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph in the preparation of GLP-1 receptor agonist.
[0088] The present invention also provides the use of a compound of Formula I or Formula II or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph thereof in the preparation of a drug for preventing and / or treating a disease associated with stimulating the GLP-1 receptor. The drug directly or indirectly treats or alleviates the disease by stimulating the GLP-1 receptor.
[0089] The diseases associated with stimulating GLP-1 receptors include diabetes, diabetic complications, metabolic syndrome, obesity, non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, Parkinson's disease, Alzheimer's disease, hypertension, hyperlipidemia, atherosclerosis, cardiovascular risk, coronary heart disease or stroke.
[0090] Beneficial effects:
[0091] The present invention provides a class of selenium-containing compounds, which have a complete GLP-1R-cAMP signaling pathway agonist effect (E max ), and the compound GLP-1R-cAMP half-effective concentration (EC 50 ) all reached nanomolar levels, and the EC 50 The selenium-containing compounds provided by the present invention have the prospect of being developed into drugs for preventing and / or treating diseases that are directly or indirectly treated or alleviated by stimulating the GLP-1 receptor. BRIEF DESCRIPTION OF THE DRAWINGS
[0092] Figure 1 This is the standard curve of rHLM test of compound 1.
[0093] Figure 2 This is the standard curve for rHLM test of PF-06882961.
[0094] Figure 3 This is the PK test ct curve of PF-06882961.
[0095] Figure 4 This is the PK test ct curve of the low-dose group of compound 1.
[0096] Figure 5 This is the PK test ct curve of the high-dose group of compound 1. DETAILED DESCRIPTION
[0097] The following is a detailed description of the essential contents of the present invention in conjunction with the embodiments, but the protection scope of the present invention is not limited thereto. The experimental methods without specific conditions in the embodiments of the present invention are usually conventional conditions, or the conditions recommended by the raw material or commodity manufacturer; the reagents without source are usually conventional reagents available through commercial channels.
[0098] Identification, characterization and purity determination methods of compounds:
[0099] 1. NMR: Compounds of the present invention 1 H-NMR spectra were measured using a Bruker nuclear magnetic resonance spectrometer (300 MHz) and a Bruker nuclear magnetic resonance spectrometer (500 MHz). 13 The C-NMR spectrum was measured using a Bruker nuclear magnetic resonance spectrometer (300 MHz). Chemical shifts (δ) are expressed in ppm using tetramethylsilane as an internal standard (0.00 ppm). 1 H-NMR notation: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of a doublet, dt = doublet of a triplet. Coupling constants, when given, are given in Hz.
[0100] 2. MS: The mass spectra of the compounds of the present invention were measured using a Shimadzu LC / MS-8050 triple quadrupole mass spectrometer, using ESI as the ionization method, and the molecular weight was accurate to one decimal place.
[0101] 3. HRMS: The high-resolution mass spectra of the compounds of the present invention are measured by LC / MS mass spectrometers of Shimadzu and Agilent, the test method is Q-TOF, and the molecular weight is accurate to four decimal places.
[0102] 4. Purity determination: The purity of the compounds of the present invention was determined using a Shimadzu LC-20AT high performance liquid chromatograph. The test conditions were: Agilent XDS-C18 chromatographic column (4.6 mm*250 mm), mobile phase methanol: water (containing 0.1% formic acid) = 70:30, the test compound sample was a chromatographic methanol solution with a concentration of about 1 mg / mL, the injection volume was 10 μL, the measurement wavelength was 254 nm, and the detection time was 10 min. The purity was measured using retention time (t R ) and area ratio (%), accurate to two decimal places.
[0103] Example 1 Preparation of Compound 1
[0104] (S)-2-(4-(6-(4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 1)
[0105]
[0106] Compound 1 was prepared using starting material 1-1 according to the following route.
[0107]
[0108] Step 1: Preparation of 1-(tert-butyl)-4-methyl-4-(6-bromopyridin-2-yl)piperidine-1,4-dicarboxylic acid (Compound 1-3)
[0109] The raw materials 2,6-dibromopyridine (compound 1-1, 1.6 g, 6.7 mmol) and N-Boc-piperidine-4-carboxylic acid methyl ester (compound 1-2, 1.75 g, 8.1 mmol) were dissolved in 3 mL of anhydrous THF. 2 Cool down to -78°C under protection. Slowly inject 17mL of LiHMDS THF solution (17mmol), react for 30min, warm to room temperature and stir for 2.5h. After the reaction is completed by TLC detection, add dilute HCl solution to the reaction solution and adjust the pH to neutral. The reaction solution is extracted with EA, washed twice with saturated sodium chloride solution, and concentrated to obtain a colorless oily liquid, namely compound 1-3 (2.06g, 77.1%). 1 H NMR (300 MHz, DMSO-d 6 )δ7.78(t,J=7.8Hz,1H),7.59(dd,J=7.9,0.7Hz,1H),7.53-7.49(m,1H),3.70(d,J=4.4Hz,1H) ,3.65(s,4H),3.08(s,2H),2.35-2.23(m,2H),1.97(ddd,J=13.9,7.2,3.2Hz,2H),1.41(s,9H). LC-MS:[M+H] + =398.1 / 400.1 (Br isotope).
[0110] Step 2: Preparation of 4-(6-bromopyridin-2-yl)-1-(tert-butyloxycarbonyl)piperidine-4-carboxylic acid (Compound 1-4)
[0111] Intermediate 1-3 (2.06 g, 5.16 mmol) was dissolved in 20 mL methanol, and NaOH aqueous solution (2 M, 26 mL) was added dropwise, and heated and stirred at 60°C for 2 h. The reaction was completed after TLC detection. Dilute hydrochloric acid was acidified to pH less than 6, and EA was extracted and concentrated to obtain white crystals, which were directly used for the next step without purification.
[0112] Step 3: Preparation of tert-butyl 4-(6-bromopyridin-2-yl)piperidine-1-carboxylate (Compound 1-5)
[0113] The intermediate 1-4 was dissolved in 45 mL of 1,2-dichloroethane (DCE), and heated to 95°C for 4 h. After the reaction was completed by TLC, the product 1-5 was dried under reduced pressure to obtain a light yellow-white solid (1.52 g, 86.4%). 1 H NMR (300 MHz, DMSO-d 6 )δ7.70(t,J=7.7Hz,1H),7.49(d,J=7.8Hz,1H),7.37(d,J=7.6Hz,1H),4.07(d,J=13.1Hz,2H),2 .86(tt,J=11.9,2.8Hz,3H), 1.83(d,J=12.8Hz,2H), 1.55(td,J=12.5,4.2Hz,2H), 1.43(s,9H). LC-MS:[M+H] + =340.1 / 341.9.
[0114] Step 4: Preparation of tert-butyl 4-(6-selenohydroxypyridin-2-yl)piperidine-1-carboxylate (Compound 1-6)
[0115] NaOH (22 mg, 0.53 mmol) and elemental selenium powder (42 mg, 0.53 mmol) were dissolved in 3 mL of anhydrous DMF. 2 After protection, hydrazine hydrate (80%, 18μL, 0.29mmol) was injected, heated to 40℃ and stirred for 2h. The anhydrous DMF solution of intermediate 1-5 (100mg, 0.29mmol) was added to the reaction system, heated to 160℃ and stirred for 4h. TLC showed that the reaction was complete. The reaction solution was filtered, extracted with equal volumes of water and EA, concentrated and purified by column chromatography (elution system: petroleum ether: ethyl acetate = 30: 1, v / v) to obtain a yellow solid, namely compound 1-6 (55mg, 55.2%). 1 H NMR (300 MHz, DMSO-d 6)δ7.71–7.55(m,2H),7.24–7.09(m,1H),4.11–3.98(m,2H),2.90–2.72(m,3H),1.84–1.73(m,2H),1.53(td,J=12.5,4.2Hz,2H),1.42(s,9H). LC-MS:[M+H] + =343.1.
[0116] Step 5: Preparation of tert-butyl 4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidine-1-carboxylate (Compound 1-8)
[0117] Intermediate 1-6 (411 mg, 1.20 mmol) was suspended in 10 mL PEG-400, N 2 Protection. Add NaBH 4 (136 mg, 3.60 mmol), stirred at room temperature for 0.5 h. Add 4-cyano-2-fluorobenzyl bromide (compound 1-7, 257 mg, 1.20 mmol), stir for 15 min, and white insoluble matter precipitates in the system. TLC shows that the reaction is complete, and the reaction solution is extracted with equal volumes of water and EA, and purified by column chromatography (elution system is petroleum ether: ethyl acetate = 50: 1, v / v) to obtain a colorless oily liquid, namely compound 1-8 (420 mg, 73.7%).
[0118] 1 H NMR(300MHz,Chloroform-d)δ7.66(t,J=7.7Hz,1H),7.59–7.54(m,1H),7.49(q,J=1.6Hz,1H),7.48–7.43(m,1H),7.28(d,J=8.1Hz,1H),7.07 (d,J=7.6Hz,1H),4.73–4.58(m,2H),4.52–4.27(m,2H),2.99(tt,J=12.0,4.1Hz,3H),2.06(d,J=12.9Hz,2H),1.98–1.88(m,2H),1.63(s,9H). LC-MS:[M+H] + =476.2.
[0119] Step 6: Preparation of 3-fluoro-4-((6-(piperidin-4-yl)pyridin-2-yl)seleno)methyl)benzonitrile (Compound 1-9) p-toluenesulfonate
[0120] Intermediate 1-8 (420 mg, 0.88 mmol) was dissolved in 10 mL EA and p-TSA·H 2O (502 mg, 2.64 mmol), heated and stirred at 60°C, and the reaction progress was monitored by TLC. After the reaction was completed, the solvent was evaporated to obtain a crude compound 1-9, which was directly used in the next step without purification.
[0121] Step 7: Preparation of (S)-2-(4-(6-(4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (Compound 1-11)
[0122] The crude intermediate 1-9 was dissolved in 10 mL MeCN, and the raw material (S)-2-(chloromethyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (compound 1-10, 235 mg, 0.80 mmol) and K were added. 2 CO 3 (552 mg, 4.00 mmol), heated to 50°C and stirred. TLC monitored the reaction to be complete. Purification by column chromatography (elution system: dichloromethane: methanol = 100: 1, v / v) gave a pale white oil, namely compound 1-11 (247 mg, 48.8%). 1 H NMR(300MHz,Chloroform-d)δ8.09(d,J=1.6Hz,1H),7.92–7.87(m,1H),7.70(d,J=7.7Hz,1H),7.43(t,J=7 .6Hz,1H),7.32(t,J=7.7Hz,1H),7.25(s,2H),7.04(d,J=7.8Hz,1H),6.86(d,J=7.7Hz,1H),5.14(d,J=6.0 Hz,1H),4.69–4.49(m,3H),4.44(d,J=1.4Hz,2H),4.32(dt,J=9.7,6.2Hz,1H),3.92(d,J=11.6Hz,2H),3.8 8(d,J=2.7Hz,3H),2.97(s,2H),2.78–2.59(m,2H),2.45–2.35(m,1H),2.24(s,2H),1.83(d,J=25.3Hz,4H). LC-MS:[M+H] + =634.2.
[0123] Step 8: Preparation of Compound 1
[0124] Intermediate 1-11 (247 mg, 0.39 mmol) was dissolved in 15 mL MeCN, and an aqueous solution of TBD (114 mg, 0.82 mmol) was added and stirred at room temperature overnight. TLC detected that the reaction was complete, and the pH was adjusted to 5-6 using an aqueous solution of CA. DCM was extracted, concentrated, and purified by column chromatography (elution system: dichloromethane: methanol = 30: 1, v / v) to obtain dark white solid compound 1 (152 mg, 62.9%).
[0125] 1 H NMR (300 MHz, DMSO-d 6 )δ12.80(s,1H),8.28(s,1H),7.81(d,J=9.2Hz,2H),7.72–7.49(m,4H),7.29(d, J=7.9Hz,1H),7.08(d,J=7.5Hz,1H),5.11(s,1H),4.72(dd,J=37.1,11.4Hz,2H), 4.52 (s, 2H), 4.40 (q, J = 8.9, 8.4 Hz, 2H), 3.90 (dd, J = 54.5, 13.8 Hz, 2H), 3.12–2.82 (m, 2H), 2.79–2.55 (m, 2H), 2.44 (s, 1H), 2.31–2.09 (m, 2H), 1.90–1.68 (m, 4H). HRMS (ESI): calculated value C 31 H 30 FN 5 O 3 Se, [M+H] + 620.1506, found 620.1556. HPLC: t R =2.89min, purity 99.56%.
[0126] Example 2 Preparation of Compound 2
[0127] (S)-2-(4-(6-benzylseleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 2)
[0128]
[0129] Compound 2 was synthesized using benzyl bromide and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 2 was a white solid, 50.4 mg in total, with a yield of 62.5%. 1 H NMR (300 MHz, DMSO-d 6)δ8.27(d,J=1.6Hz,1H),7.80(dd,J=8.5,1.6Hz,2H),7.76–7.69(m,2H),7.64(d,J=8.5Hz,1H),7.60–7.50( m,3H),7.28(d,J=7.7Hz,1H),7.07(d,J=7.5Hz,1H),5.18–5.03(m,1H),4.86–4.60(m,2H),4.53(s,2H),4.36 (dt, J = 14.7, 6.3 Hz, 2H), 4.04–3.69 (m, 2H), 3.28 (d, J = 6.0 Hz, 1H), 3.04 (d, J = 10.9 Hz, 1H), 2.88 (d, J = 11.1 Hz, 1H), 2.65 (td, J = 17.0, 14.4, 6.4 Hz, 2H), 2.21 (dd, J = 22.5, 11.2 Hz, 2H), 1.86 (td, J = 13.0, 12.5, 6.7 Hz, 4H). HRMS (ESI): calculated value C 30 H 32 N 4 O 3 Se,[M+H] + 577.1712, measured value 577.1708. HPLC: t R =2.45min, purity 97.02%.
[0130] Example 3 Preparation of Compound 3
[0131] (S)-2-(4-(6-(4-cyanobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 3)
[0132]
[0133] Compound 3 was synthesized using 4-cyanobenzyl bromide and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 3 was a white solid, 46.7 mg in total, with a yield of 42.2%. 1 H NMR (300 MHz, DMSO-d 6)δ12.83(s,1H),8.30(d,J=1.6Hz,1H),7.88–7.71(m,4H),7.67(d,J=8.4Hz,1H),7.63–7.52(m,3H) ,7.31(d,J=7.8Hz,1H),7.10(d,J=7.6Hz,1H),5.18–5.04(m,1H),4.89–4.63(m,2H),4.56(s,2H),4 .41 (tq, J = 12.3, 5.6 Hz, 2H), 4.06-3.76 (m, 2H), 3.29 (d, J = 6.0 Hz, 1H), 3.07 (d, J = 11.1 Hz, 1H), 2.91 (d, J = 11.0 Hz, 1H), 2.80-2.60 (m, 2H), 2.24 (dd, J = 22.4, 11.1 Hz, 2H), 1.88 (dd, J = 15.5, 9.4 Hz, 4H). HRMS (ESI): calculated value C 31 H 31 N 5 O 3 Se,[M+H] + 602.1665, found 602.1651. HPLC: t R =3.15min, purity 98.92%.
[0134] Example 4 Preparation of Compound 4
[0135] (S)-2-(4-(6-(4-chlorobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 4)
[0136]
[0137] Compound 4 was synthesized using 4-chlorobenzyl bromide and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 4 was a white solid, 43.7 mg in total, with a yield of 47.1%. 1 H NMR (300 MHz, DMSO-d 6)δ12.74(s,1H),8.27(s,1H),7.80(d,J=8.5Hz,1H),7.65(d,J=8.6Hz,1H),7.52(t,J= 7.7Hz,1H),7.40(d,J=8.1Hz,2H),7.28(dd,J=15.0,7.9Hz,3H),7.06(d,J=7.6Hz,1H) ,5.09(d,J=7.3Hz,1H),4.86–4.58(m,2H),4.54–4.29(m,4H),4.09–3.72(m,2H),3.27(t,J=6.0Hz,1H),3.11–2.83(m,2H),2.67(s,2H),2.23(d,J=22.0Hz,2H),1.84(s,4H). HRMS(ESI): calculated value C 30 H 31 C1N 4 O 3 Se,[M+H] + 611.1323, found 611.1317. HPLC: t R =5.39min, purity 96.75%.
[0138] Example 5 Preparation of Compound 5
[0139] (S)-2-(4-(6-(2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 5)
[0140]
[0141] Compound 5 was synthesized using 2-fluorobenzyl bromide and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 5 was a white solid, 42.3 mg in total, with a yield of 38.3%. 1 H NMR (300 MHz, DMSO-d 6)δ8.27(s,1H),7.85–7.75(m,1H),7.65(d,J=8.5Hz,1H),7.53(t,J=7.7Hz,1H),7.45(t,J= 7.5Hz,1H),7.25(dd,J=10.6,7.0Hz,2H),7.20–7.01(m,3H),5.10(d,J=7.7Hz,1H),4.88–4. 57 (m, 2H), 4.48 (s, 2H), 4.43–4.31 (m, 2H), 4.09–3.71 (m, 2H), 2.96 (dd, J=49.8, 11.0 Hz, 2H), 2.80–2.59 (m, 2H), 2.44 (d, J=8.8 Hz, 1H), 2.35–2.11 (m, 2H), 1.85 (dt, J=13.5, 6.5 Hz, 4H). HRMS (ESI): calculated value C 30 H 31 FN 4 O 3 Se,[M+H] + 595.1618, measured value 595.1617.HPLC: t R =6.51min, purity 94.38%.
[0142] Example 6 Preparation of Compound 6
[0143] (S)-2-(4-(6-(4-chloro-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 6)
[0144]
[0145] Compound 6 was synthesized using 4-chloro-2-fluorobenzyl bromide and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 6 was a white solid, with a total of 62.5 mg and a yield of 75.9%. 1 H NMR (300 MHz, DMSO-d 6)δ12.74(s,1H),8.27(s,1H),7.80(d,J=8.5Hz,1H),7.65(d,J=8.6Hz,1H),7.52(t,J= 7.7Hz,1H),7.40(d,J=8.1Hz,2H),7.28(dd,J=15.0,7.9Hz,3H),7.06(d,J=7.6Hz,1H) ,5.09(d,J=7.3Hz,1H),4.86–4.58(m,2H),4.54–4.29(m,4H),4.09–3.72(m,2H),3.27(t,J=6.0Hz,1H),3.11–2.83(m,2H),2.67(s,2H),2.23(d,J=22.0Hz,2H),1.84(s,4H). HRMS(ESI): calculated value C 30 H 30 CIF 4 O 3 Se,[M+H] + 629.1256, found 629.1218. HPLC: t R =5.79min, purity 97.66%.
[0146] Example 7 Preparation of Compound 7
[0147] (S)-2-(4-(6-((2-methoxy-4-(trifluoromethyl)benzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 7)
[0148]
[0149] Compound 7 was synthesized using 2-methoxy-4-(trifluoromethyl)benzyl bromide and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 7 was a white solid, 45 mg in total, with a yield of 60.5%. 1 H NMR (300 MHz, DMSO-d 6)δ8.26(s,1H),7.85–7.76(m,1H),7.64(d,J=8.5Hz,1H),7.52(dt,J=7.8,3.8Hz,2H),7.29–7.15( m,3H),7.06(d,J=7.6Hz,1H),5.10(d,J=7.6Hz,1H),4.80(dd,J=15.0,7.2Hz,1H),4.71–4.60(m,1H ), 4.48–4.31 (m, 4H), 3.98 (d, J = 13.5 Hz, 1H), 3.88 (s, 3H), 3.79 (d, J = 13.4 Hz, 1H), 3.05 (d, J = 11.0 Hz, 1H), 2.90 (d, J = 11.1 Hz, 1H), 2.71 (s, 2H), 2.44 (d, J = 8.4 Hz, 1H), 2.48–2.14 (m, 2H), 1.85 (s, 4H). HRMS (ESI): calculated value C 32 H 33 F 3 N 4 O 4 Se,[M+H] + 675.1619, found 675.1657. HPLC: t R =7.22min, purity 96.63%.
[0150] Example 8 Preparation of Compound 8
[0151] (S)-2-(4-(6-(4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperazine-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 8)
[0152]
[0153] Compound 8 was prepared using starting materials 1-1 and 8-2 according to the following route.
[0154]
[0155] Step 1: Preparation of tert-butyl 4-(6-bromopyridin-2-yl)piperazine-1-carboxylate (Compound 8-2)
[0156] The raw material 2,6-dibromopyridine (compound 1-1, 346 mg, 1.46 mmol) was dissolved in 10 mL DMF, and the raw material 1-Boc-piperazine (compound 8-1, 353 mg, 1.89 mmol) and K 2 CO 3(405 mg, 2.93 mmol), heated and stirred at 80°C for 4 h. TLC showed that the reaction was complete, and purified by column chromatography (elution system: petroleum ether: ethyl acetate = 20: 1, v / v) to obtain a white solid 8-2 (331 mg, 66.1%). 1 H NMR (300MHz, Chloroform-d) δ7.33 (dd, J=8.4, 7.4Hz, 1H), 6.81 (d, J=7.5Hz, 1H), 6.56 (d, J=8.3Hz, 1H), 3.56 (s, 8H), 1.51 (s, 9H). LC-MS:[M+H] + =342.1.
[0157] Step 2: Preparation of tert-butyl 4-(6-selenohydroxypyridin-2-yl)piperazine-1-carboxylate (Compound 8-3)
[0158] NaOH (180 mg, 4.50 mmol) and elemental selenium powder (356 mg, 4.50 mmol) were dissolved in 6 mL of anhydrous DMF. 2 After protection, hydrazine hydrate (80%, 150μL, 3.0mmol) was injected, heated to 40℃ and stirred for 2h. Intermediate 8-2 (514mg, 1.50mmol) was dissolved in 5mL of anhydrous DMF and added to the reaction system, heated to 160℃ and stirred for 4h. TLC showed that the reaction was complete. The reaction solution was filtered, extracted with equal volumes of water and EA, concentrated and purified by column chromatography (elution system: petroleum ether: ethyl acetate = 15: 1, v / v) to obtain a yellow solid 8-3 (331mg, 64.3%). 1 H NMR (300MHz, Chloroform-d) δ7.45 (t, J = 7.4 Hz, 1H), 7.12 (dd, J = 7.5, 1.5 Hz, 1H), 6.87 (dd, J = 7.5, 1.5 Hz, 1H), 6.19 (s, 1H), 3.62 (s, 8H), 1.46 (s, 9H). LC-MS:[M+H] + =344.0.
[0159] Step 3: Preparation of tert-butyl 4-(6-(4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperazine-1-carboxylate (Compound 8-4)
[0160] Intermediate 8-3 (169 mg, 0.49 mmol) was suspended in 10 mL PEG-400, N 2 Protection. Add NaBH 4(56mg, 0.49mmol), stirred at room temperature for 0.5h. Add 4-cyano-2-fluorobenzyl bromide (compound 1-7, 105mg, 0.49mmol), stir for 15min, and white insoluble matter precipitates in the system. TLC shows that the reaction is complete, and the reaction solution is extracted with equal volumes of water and EA, and purified by column chromatography (elution system is petroleum ether: ethyl acetate = 30: 1, v / v) to obtain a colorless oily liquid, namely compound 8-4 (128mg, 73.7%). 1H NMR(300MHz,Chloroform-d)δ7.54(t,J=7.7Hz,1H),7.43–7.34(m,3H),6.72(d,J= 7.4Hz, 1H), 6.47 (d, J = 8.4Hz, 1H), 4.51 (d, J = 1.4Hz, 2H), 3.62 (s, 8H), 1.55 (s, 9H). LC-MS:[M+H] + =477.1.
[0161] Step 4: Preparation of compound 8
[0162] According to the synthesis method of compound 1, intermediate 8-4 was used as a raw material to prepare compound 8. Compound 8 was a light yellow solid, with a total of 64.5 mg and a yield of 43.7%. 1 H NMR (300 MHz, DMSO-d 6 )δ8.28(d,J=1.6Hz,1H),7.86–7.77(m,2H),7.69–7.55(m,3H),7.35(t,J=7.9Hz,1 H),6.69(d,J=7.4Hz,1H),6.59(d,J=8.4Hz,1H),5.11(d,J=7.3Hz,1H),4.81(dd,J= 15.4,7.2 Hz, 1H), 4.71–4.62 (m, 1H), 4.55–4.33 (m, 4H), 4.05–3.77 (m, 2H), 3.52 (d, J = 5.7 Hz, 4H), 2.70 (d, J = 9.2 Hz, 1H), 2.57 (d, J = 5.2 Hz, 4H), 2.42 (d, J = 9.0 Hz, 1H). HRMS (ESI): calculated value C 30 H 29 FN 6 O 3 Se,[M+H] + 621.1523, measured value 621.1523. HPLC: t R =5.00min, purity 97.48%.
[0163] Example 9 Preparation of Compound 9
[0164] (S)-2-(4-(6-(4-chloro-2-fluorobenzyl)seleno)pyridin-2-yl)piperazine-1-methyl)-1-(oxetane-2-methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 9)
[0165]
[0166] Compound 9 was synthesized from the raw material 4-chloro-2-fluorobenzyl bromide and intermediate 8-4 according to the synthetic route of compound 8. Compound 9 was a yellow solid, with a total of 79.4 mg and a yield of 62.5%. 1 H NMR (300 MHz, DMSO-d 6 )δ9.07(s,1H),8.22(s,1H),7.82(d,J=8.4Hz,1H),7.57(d,J=8.4Hz,1H),7.47–7.30(m,3H),7.20(dd ,J=8.3,2.2Hz,1H),6.68(d,J=7.4Hz,1H),6.58(d,J=8.4Hz,1H),5.10(dt,J=9.4,4.7Hz,1H),4.72(dd d, J = 40.5, 15.3, 5.1 Hz, 2H), 4.49 (q, J = 7.3 Hz, 1H), 4.38 (d, J = 9.1 Hz, 3H), 4.04-3.94 (m, 1H), 3.81 (d, J = 13.4 Hz, 1H), 3.27 (t, J = 5.9 Hz, 4H), 3.20 (t, J = 5.8 Hz, 4H), 2.77-2.66 (m, 1H), 2.44 (t, J = 9.2 Hz, 1H). HRMS (ESI): calculated value C 29 H 29 CIF 5 O 3 Se,[M+H] + 630.1108, found 630.1180. HPLC: t R =4.99min, purity 94.42%.
[0167] Example 10 Preparation of Compound 10
[0168] 2-(4-(6-(4-cyano-2-fluorobenzyl)selensulfonyl)pyridin-2-yl)piperidin-1-methyl)-1-((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 10)
[0169]
[0170] Compound 10 was prepared using starting materials 1-9 according to the following route.
[0171]
[0172] Step 1: Preparation of 3-fluoro-4-((6-(piperidin-4-yl)pyridin-2-yl)selensulfonyl)methyl)benzonitrile (Compound 10-1)
[0173] The crude intermediate 1-9 (108 mg, 0.29 mmol) was dissolved in 5 mL DCM and 5 mL MeOH and cooled to 0°C in an ice bath. NCS (46.5 mg, 0.35 mmol) was added and stirred for 0.5 h. 5 mL DCM was added to the system, and a 10% aqueous NaOH solution (2.9 mL, 10 mL / mmol) was added and stirred for 5 min. TLC showed that the reaction was complete. An equal volume of water and DCM was used for extraction, and the mixture was concentrated and purified by column chromatography (elution system was dichloromethane: methanol = 50: 1, v / v) to obtain a colorless oily liquid 10-1 (81 mg, 71.6%).
[0174] 1 H NMR(300MHz,Chloroform-d)δ7.72(t,J=7.7Hz,1H),7.39(ddd,J=17.5,7.8,1.3Hz,2H),7.27–7.14(m,3H),4 .35–4.12(m,2H),3.33–3.21(m,2H),2.84(m,J=22.2,14.8,11.9,3.2Hz,3H),1.99–1.71(m,4H), LC-MS: [M+H] + =392.0.
[0175] Step 2: Preparation of compound 10
[0176] According to the synthesis method of compound 1, intermediate 10-1 was used as a raw material to prepare compound 10. Compound 10 was a white solid, 18.0 mg in total, with a yield of 40.5%. 1 H NMR (300 MHz, DMSO-d 6)δ9.07(s,1H),8.22(s,1H),7.82(d,J=8.4Hz,1H),7.57(d,J=8.4Hz,1H),7.47–7.30(m,3H),7.20(dd ,J=8.3,2.2Hz,1H),6.68(d,J=7.4Hz,1H),6.58(d,J=8.4Hz,1H),5.10(dt,J=9.4,4.7Hz,1H),4.72(dd d, J = 40.5, 15.3, 5.1 Hz, 2H), 4.49 (q, J = 7.3 Hz, 1H), 4.38 (d, J = 9.1 Hz, 3H), 4.04-3.94 (m, 1H), 3.81 (d, J = 13.4 Hz, 1H), 3.27 (t, J = 5.9 Hz, 4H), 3.20 (t, J = 5.8 Hz, 4H), 2.77-2.66 (m, 1H), 2.44 (t, J = 9.2 Hz, 1H). HRMS (ESI): calculated value C 31 H 30 CIF 5 O 4 Se,[M+H] + 630.1520, found 630.1579. HPLC: t R =4.99min, purity 94.42%.
[0177] Example 11 Preparation of Compound 11
[0178] (S)-2-(4-(6-(4-cyano-2-fluorophenyl)selenomethyl)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 11)
[0179]
[0180] Compound 11 was prepared using starting material 11-1 according to the following route.
[0181]
[0182] Step 1: Preparation of 3-fluoro-4-hydrogenselenidebenzonitrile (Compound 11-2)
[0183] NaOH (243 mg, 6.07 mmol) and elemental selenium powder (480 mg, 6.07 mmol) were dissolved in 5 mL of anhydrous DMF. 2After protection, hydrazine hydrate (80%, 128μL, 2.02mmol) was injected, heated to 40℃ and stirred for 2h. 3-Fluoro-4-iodobenzonitrile (compound 11-1, 500mg, 2.02mmol) was dissolved in 5mL of anhydrous DMF solution and added to the reaction system, heated to 160℃ and stirred for 4h. TLC showed that the reaction was complete. The reaction solution was filtered, extracted with equal volumes of water and EA, concentrated and purified by column chromatography (elution system: petroleum ether: ethyl acetate = 20: 1, v / v) to obtain a yellow solid, namely compound 11-2 (410mg, 50.9%). 1 H NMR (300MHz, Chloroform-d) δ7.71 (dd, J=8.1, 6.8Hz, 1H), 7.45–7.30 (m, 2H). LC-MS:[M+H] + =201.9.
[0184] Step 2: Preparation of tert-butyl 6-(hydroxymethyl)-3',6'-dihydro-(2,4'-bipyridine)-1'(2'H)-carboxylate (Compound 11-5)
[0185] 6-Chloro-2-hydroxymethylpyridine (Compound 11-3, 231 mg, 1.62 mmol) was dissolved in 20 mL of dioxane and 2 mL of H 2 O, add N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (Compound 11-4, 999 mg, 3.23 mmol), Pd(dppf)Cl 2 (118 mg, 0.16 mmol) and Cs 2 CO 3 (1153 mg, 3.55 mmol), N 2 The reaction mixture was protected and heated to 90°C and stirred for 2 h. TLC showed that the reaction was complete. The reaction solution was extracted with an equal volume of water and EA. The mixture was concentrated and purified by column chromatography (elution system: petroleum ether: ethyl acetate = 50:1, v / v) to obtain a colorless oily liquid, namely compound 11-5 (369 mg, 78.7%). 1 H NMR(300MHz,Chloroform-d)δ7.67(t,J=7.7Hz,1H),7.11(d,J=7.7Hz,2H),6.56(s,1H),4.78(s,2H) ,4.31(s,2H),2.91(dd,J=12.2,4.3Hz,2H),1.99(s,2H),1.79(dd,J=12.6,4.4Hz,2H),1.54(s,9H). LC-MS: [M+H]+=291.3.
[0186] Step 3: Preparation of tert-butyl 4-(6-(hydroxymethyl)pyridin-2-yl)piperidine-1-carboxylate (Compound 11-6)
[0187] Intermediate 11-5 (369 mg, 1.27 mmol) was dissolved in 10 mL MeOH, and an equal amount of Pd / C (10%) and H 2 Replacement, stirring for 2h, LC-MS / MS showed the reaction was complete, filtration, and the solvent was spin-dried to obtain a colorless oily liquid, namely compound 11-6 (369 mg, 99.2%). 1 H NMR(300MHz,Chloroform-d)δ7.67(t,J=7.7Hz,1H),7.11(d,J=7.7Hz,2H),4.78(s ,2H),4.31(s,2H),2.91(m,4H),1.99(s,2H),1.79(d,J=12.6Hz,2H),1.54(s,9H). LC-MS: [M+H]+=293.3.
[0188] Step 4: Preparation of tert-butyl 4-(6-(bromomethyl)pyridin-2-yl)piperidine-1-carboxylate (Compound 11-7)
[0189] Intermediate 11-6 (369 mg, 1.27 mmol) was dissolved in 10 mL DCM and CBr was added. 4 (420 mg, 1.27 mmol) and PPh 3 (499 mg, 1.90 mmol), stirred at room temperature for 3 h, TLC showed the reaction was complete, and purified by column chromatography (elution system: petroleum ether: ethyl acetate = 20: 1, v / v) to obtain a yellow-white solid, namely compound 11-7 (234 mg, 52.2%). 1 H NMR(300MHz,Chloroform-d)δ7.64(t,J=7.7Hz,1H),7.31–7.27(m,1H),7.07(d,J=7.8Hz,1H),4.53(s,2H),4. 25(d,J=13.1Hz,2H), 2.86(d,J=12.6Hz,3H), 1.92(d,J=13.1Hz,2H), 1.76–1.63(m,2H), 1.48(d,J=1.1Hz,9H). LC-MS: [M+H]+=355.1.
[0190] Step 5: Preparation of tert-butyl 4-(6-(4-cyano-2-fluorophenyl)selenomethyl)pyridin-2-yl)piperidine-1-carboxylate (Compound 11-8)
[0191] Intermediate 11-2 (66 mg, 0.33 mmol) and NaBH4 (37.4 mg, 0.99 mmol) was dissolved in 2 mL of anhydrous ethanol, N 2 After protection, an ethanol solution (3 mL) of intermediate 11-7 (234 mg, 0.66 mmol) was added dropwise and stirred at room temperature overnight. TLC showed that the reaction was complete, and the reaction solution was extracted with equal volumes of water and EA, and purified by column chromatography (elution system: petroleum ether: ethyl acetate = 30: 1, v / v) to obtain a colorless oily liquid, namely compound 11-8 (90 mg, 73.7%). 1 H NMR(300MHz,Chloroform-d)δ7.72(dt,J=8.1,5.7Hz,1H),7.56(td,J=10.4,9.1,5.3Hz,1H),7.37–7.22(m,2H),7.15(d,J=7.6Hz,1H),7 .01(d,J=7.7Hz,1H), 4.29(d,J=21.9Hz,4H), 2.82(d,J=12.6Hz,3H), 1.86(d,J=13.0Hz,2H), 1.69(dt,J=12.4,6.7Hz,2H), 1.49(s,9H). LC-MS: [M+H]+=476.1.
[0192] Step 6: Preparation of compound 11
[0193] According to the synthesis method of compound 1, intermediate 11-8 was used as a raw material to prepare compound 10. Compound 10 was a dark white solid, 35 mg in total, with a yield of 67.4%. 1 H NMR (300 MHz, DMSO-d 6)δ13.12–12.50(m,1H),8.28(d,J=1.6Hz,1H),7.98–7.87(m,1H),7.86–7.74(m,2H),7.72–7.57(m,3H),7.30(d,J=7.7Hz,1H) ,7.13(d,J=7.7Hz,1H),5.11(dt,J=9.3,4.7Hz,1H),4.83(dd,J=15.2,7.1Hz,1H),4.68(dd,J=15.1,2.8Hz,1H),4.56–4.44(m , 3H), 4.40 (dt, J = 9.0, 5.9 Hz, 1H), 3.97 (d, J = 13.5 Hz, 1H), 3.79 (d, J = 13.4 Hz, 1H), 3.01 (d, J = 11.0 Hz, 1H), 2.87 (d, J = 11.1 Hz, 1H), 2.80–2.68 (m, 1H), 2.60 (d, J = 11.1 Hz, 1H), 2.45 (dd, J = 9.9, 7.4 Hz, 1H), 2.30–2.10 (m, 2H), 1.70 (dd, J = 24.9, 11.4 Hz, 4H). HRMS (ESI): calculated value C 31 H 30 FN 5 O 3 Se,[M+H] + 620.1571, measured value 620.1531. HPLC: t R =3.26min, purity 98.20%.
[0194] Example 12 Preparation of Compound 12
[0195] (S)-2-(4-(6-(4-cyano-2-fluorobenzyl)selenoyl)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-ylhydroxylamine (Compound 12)
[0196]
[0197] Compound 12 was prepared using compound 1 as a raw material according to the following route.
[0198]
[0199] Step 1: Preparation of intermediate 12-2
[0200] Compound 1 (70 mg, 0.11 mmol) was dissolved in 5 mL of anhydrous DMF, and EDCI (65 mg, 0.34 mmol), HOBt (45.8 mg, 0.34 mmol), DIPEA (59 μL, 0.34 mmol) and NH 2 OTHP (compound 12-1, 26.5 mg, 0.22 mmol), stirred at room temperature for 3 h. TLC detected that the reaction was complete, and the reaction solution was extracted with equal volumes of water and EA, and the organic phases were combined and concentrated to obtain the crude intermediate 12-2 (58 mg, 48.8%). LC-MS: [M+H]+=719.2.
[0201] Step 2: Preparation of compound 12
[0202] Intermediate 12-2 (58 mg, 0.08 mmol) was dissolved in 5 mL of methanol, and a methanol solution of TFA (6.2 μL, 0.08 mmol) was added dropwise, and stirred at room temperature for 2 h. After TLC detection, the reaction was completed, and compound 12 was purified by column chromatography (elution system: dichloromethane: methanol = 20: 1, v / v) to obtain compound 12 as a white solid (36 mg, 70.3%). 1 H NMR (300 MHz, DMSO-d 6 )δ11.17(s,1H),8.99(s,1H),8.08(s,1H),7.81(d,J=9.8Hz,1H),7.65(d,J=8.2Hz,1H),7.61(s,3H),7.53(d,J= 7.7Hz,1H),7.29(d,J=7.6Hz,1H),7.08(d,J=7.4Hz,1H),5.13(s,1H),4.76(t,J=11.0Hz,1H),4.62(d,J=14.9Hz, 1H), 4.52 (s, 2H), 4.41 (q, J = 6.9 Hz, 2H), 3.97 (d, J = 13.4 Hz, 1H), 3.78 (d, J = 13.5 Hz, 1H), 3.03 (d, J = 11.0 Hz, 1H), 2.89 (d, J = 11.0 Hz, 1H), 2.76–2.64 (m, 3H), 2.21 (dd, J = 22.6, 11.5 Hz, 2H), 1.82 (d, J = 11.9 Hz, 4H). HRMS (ESI): calculated value C 31 H 31 FN 6 O 3 Se,[M+H] + 635.1607, found 635.1650. HPLC: t R =2.51min, purity 99.60%.
[0203] Example 13 Preparation of Compound 13
[0204] (S)-2-(4-(6-(4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxamide methylsulfonamide (Compound 13)
[0205]
[0206] Compound 13 was prepared using compound 1 as a raw material according to the following route.
[0207]
[0208] Step 1: Preparation of compound 13
[0209] Compound 1 (40 mg, 0.06 mmol) was dissolved in 5 mL of anhydrous DCM, and 2-chloro-1-methylpyridinium iodide (33 mg, 0.13 mmol), DMAP (11.8 mg, 0.10 mmol) and Et 3 N (27 μL, 0.19 mmol), stirred for 0.5 h, then added methylsulfonamide (compound 13-1, 6.8 mg, 0.07 mmol), and stirred at room temperature for 10 h. TLC detected that the reaction was complete, and the reaction solution was extracted with equal volumes of water and DCM, the organic phases were combined, concentrated, and purified by column chromatography (elution system: dichloromethane: methanol = 15: 1, v / v) to obtain compound 13, a total of 27 mg, with a yield of 60.0%. 1 H NMR (300 MHz, DMSO-d 6 )δ8.35(d,J=1.6Hz,1H),7.83(t,J=8.8Hz,2H),7.73(d,J=8.5Hz,1H),7.70–7.52(m,3H),7.32(d ,J=7.8Hz,1H),7.11(d,J=7.6Hz,1H),5.12(d,J=7.1Hz,1H),4.80(dd,J=15.3,7.0Hz,1H),4.65(d , J = 13.6 Hz, 1H), 4.50 (d, J = 21.6 Hz, 2H), 4.41 (dd, J = 9.2, 6.2 Hz, 3H), 2.86 (s, 1H), 2.79–2.64 (m, 2H), 2.41 (s, 1H), 2.27–2.12 (m, 2H), 1.98 (s, 3H), 1.94 (s, 2H), 1.47 (s, 1H), 1.34 (d, J = 4.7 Hz, 3H). HRMS (ESI): calculated value C 32 H 33 FN6 O 4 SSe,[M+H] + 697.1433, found 697.1486. HPLC: t R =2.90min, purity 93.43%.
[0210] Example 14 Preparation of Compound 14
[0211] (S)-2-(4-(6-(4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-methylsulfonylurea (Compound 14)
[0212]
[0213] Compound 14 was prepared using starting material 14-1 according to the following route.
[0214]
[0215] Step 1: Preparation of tert-butyl ((3-fluoro-4-nitrophenyl)sulfonyl)carbamate (Compound 14-2)
[0216] Dissolve tert-butyl carbamate (10.74 g, 91.7 mmol) in 100 mL of anhydrous acetonitrile. 2 Cool down to -78°C under protection. Dissolve compound 3-fluoro-4-nitrobenzenesulfonyl chloride (compound 14-1, 18.26 g, 76.4 mmol) in 150 mL of anhydrous acetonitrile and add quickly. After half an hour of reaction, warm to room temperature and stir for 1.5 hours. After the reaction is completed by TLC detection, add dilute HCl solution to the reaction solution and adjust the pH to neutral. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is purified by column chromatography (elution system is petroleum ether: ethyl acetate = 3: 1, v / v) to obtain intermediate 14-2 (10.47 g, 42.8%).
[0217] 1 H NMR (300 MHz, DMSO-d 6 )δ8.19(dd,J=8.8,7.3Hz,1H),7.78–7.65(m,2H),1.22(s,9H). LC-MS: [M+H]+=321.0.
[0218] Step 2: Preparation of (S)-tert-butyl ((4-nitro-3-((oxetanylamino-2-ylmethyl)amino)phenyl)sulfonyl)carbamate (Compound 14-3)
[0219] Dissolve intermediate 14-2 (10.47 g, 32.71 mmol) in 50 mL of acetonitrile, add DIPEA (6.83 ml, 39.25 mmol) and (S)-oxetane-2-ylmethylamine (3.42 g, 39.25 mmol), and heat to 60 ° C for 4 h. After the reaction is completed by TLC, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, and the organic layers are combined and concentrated under low pressure to remove the solvent to obtain intermediate 14-3 (9.18 g, 72.5%). 1 H NMR (300 MHz, DMSO-d 6 )δ8.41(t,J=5.7Hz,1H),8.19(d,J=8.9Hz,1H),7.49(d,J=1.8Hz,1H),7.01(dd,J=9.0,1.8Hz,1H),5 .00(t,J=5.9Hz,1H),4.62–4.39(m,2H),3.72–3.57(m,3H),2.76–2.52(m,2H),1.26(d,J=9.3Hz,9H). LC-MS: [M+H]+=388.1.
[0220] Step 3: Preparation of (S)-tert-butyl ((4-amino-3-((oxetanylamino-2-ylmethyl)amino)phenyl)sulfonyl)carbamate (Compound 14-4)
[0221] Intermediate 14-3 (9.18 g, 23.72 mmol) was dissolved in 40 mL of methanol, and 10% Pd / C (918 mg) and N 2 The temperature was raised to 50°C under protection and the reaction was continued for 2 hours. After the reaction was completed by TLC, the reaction solution was filtered through diatomaceous earth and concentrated under low pressure to remove the solvent. The residue was purified by column chromatography (elution system: dichloromethane: methanol = 100: 1, v / v) to obtain intermediate 14-4 (5.1 g, 60.2%).
[0222] 1 H NMR (300 MHz, DMSO-d 6)δ11.01(s,1H),6.99(dd,J=8.2,2.1Hz,1H),6.86(d,J=2.1Hz,1H),6.58(d,J=8.2Hz,1H),5.60(s,2H),4.95(dt,J=14.1,6.0Hz, 2H), 4.61–4.41(m,2H),3.31(ddt,J=18.9,13.2,6.9Hz,2H),2.67(dtd,J=10.9,8.1,6.2Hz,1H),2.50–2.35(m,1H),1.30(s,9H). LC-MS: [M+H]+=358.1.
[0223] Step 4: Preparation of (S)-tert-butyl ((2-(chloromethyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)sulfonyl)carbamate (Compound 14-5)
[0224] Intermediate 14-4 (5.1 g, 14.24 mmol) was dissolved in 30 mL of acetonitrile, p-toluenesulfonic acid hydrate (2.4 g, 1.42 mmol) and 2-chloro-1,1,1-trimethoxyethane (2.63 g, 17.09 mmol) were added, and the temperature was raised to 60°C for 4 h. After the reaction was completed by TLC, the reaction solution was extracted three times with equal volumes of ethyl acetate and water, the organic layers were combined and concentrated under low pressure to remove the solvent, and the residue was purified by column chromatography (elution system: dichloromethane: methanol = 200: 1, v / v) to obtain intermediate 14-5 (2.4 g, 40.6%).
[0225] 1 H NMR (300 MHz, DMSO-d 6 )δ11.64(s,1H),8.30(d,J=1.8Hz,1H),7.88(d,J=8.6Hz,1H),7.74(dd,J=8.6 ,1.8Hz,1H),5.21–5.09(m,2H),5.05(td,J=7.2,2.7Hz,1H),4.79(dd,J=15.5 ,6.9Hz,1H),4.67(dd,J=15.5,2.9Hz,1H),4.47(td,J=8.1,7.7,5.8Hz,1H),4 .32(dt,J=9.1,5.9Hz,1H),2.79–2.61(m,1H),2.46–2.29(m,1H),1.27(s,9H). LC-MS: [M+H]+ = 416.1.
[0226] Step 5: Preparation of (S)-tert-butyl ((2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)sulfonyl)carbamate (Compound 14-6)
[0227] Intermediate 1-9 (4.18 g, 5.82 mmol) was dissolved in 15 mL of acetonitrile and K 2 CO 3 (3.98g, 28.85mmol) was stirred at room temperature for 0.5h, and then compound 14-5 (2.4g, 5.77mmol) was added and the temperature was raised to 50℃ for 2h. After the reaction was completed by TLC, saturated ammonium chloride solution was added to quench. The reaction solution was extracted three times with equal volumes of ethyl acetate and water, and the organic layers were combined and concentrated under low pressure to remove the solvent. The residue was purified by column chromatography (elution system: dichloromethane: methanol = 50: 1, v / v) to obtain intermediate 14-6 (3g, 68.9%).
[0228] 1 H NMR (300 MHz, DMSO-d 6 )δ11.58(s,1H),8.23(d,J=1.7Hz,1H),7.90–7.77(m,2H),7.76–7.49(m,4H),7.30(d,J=7.8Hz,1H),7.08(d,J= 7.6Hz,1H),5.78(s,1H),5.12(t,J=8.1Hz,1H),4.82(dd,J=15.3,7.1Hz,1H),4.69(d,J=15.0Hz,1H),4.53(s,2H ),4.47–4.30(m,2H),4.03(d,J=13.6Hz,1H),3.87(d,J=13.6Hz,1H),3.07(d,J=11.0Hz,1H),2.93(d,J=11.1Hz, 1H), 2.69 (s, 2H), 2.49–2.34 (m, 1H), 2.27 (dd, J=20.3, 10.4Hz, 2H), 1.80 (dd, J=24.2, 11.6Hz, 3H), 1.27 (s, 9H). LC-MS: [M+H]+=755.2.
[0229] Step 6: Preparation of (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzo[d]imidazole-6-sulfonamide (Compound 14-7)
[0230] Intermediate 14-6 (3 g, 3.98 mmol) was dissolved in 20 mL of dichloromethane and CF 3 COOH (4.54 g, 39.8 mmol) was added and stirred at room temperature for 2 h. After the reaction was completed by TLC, saturated sodium bicarbonate solution was added to quench the reaction. The reaction solution was extracted three times with equal volumes of ethyl acetate and water, and the organic layers were combined and concentrated under low pressure to remove the solvent to obtain intermediate 14-7 (2.18 g, 83.8%).
[0231] 1 H NMR (300 MHz, DMSO-d 6 )δ8.13(d,J=1.7Hz,1H),7.84–7.50(m,6H),7.29(t,J=3.8Hz,3H),7.08(d,J=7.6Hz,1H),5.76(s ,1H),5.11(d,J=6.8Hz,1H),4.79(dd,J=15.2,7.1Hz,1H),4.70–4.60(m,1H),4.52(s,2H),4.45– 4.34(m,2H),3.98(d,J=13.5Hz,1H),3.80(d,J=13.5Hz,1H),3.03(d,J=11.2Hz,1H),2.88(d,J=1 1.2Hz, 1H), 2.68 (s, 2H), 2.43 (q, J = 8.3Hz, 1H), 2.23 (dt, J = 21.4, 11.5Hz, 2H), 1.88–1.73 (m, 3H). LC-MS: [M+H]+=655.1.
[0232] Step 7: Preparation of compound 14
[0233] Intermediate 14-7 (500 mg, 0.76 mmol) was dissolved in 5 mL of acetonitrile, and N-methylcarbamic acid phenyl ester (127 mg, 0.84 mmol) and DBU (139 mg, 0.92 mmol) were added and stirred at room temperature for 2 h. After the reaction was completed by TLC detection, saturated ammonium chloride solution was added to quench. The reaction solution was extracted three times with equal volumes of ethyl acetate and water, and the organic layers were combined and concentrated under low pressure to remove the solvent. The residue was subjected to column chromatography (elution system was dichloromethane: methanol = 20: 1, v / v) to obtain compound 14 (397 mg, 73.1%). 1 H NMR (300 MHz, DMSO-d 6)δ10.69(s,1H),8.25(d,J=1.7Hz,1H),7.87–7.76(m,2H),7.72(dd,J=8.6,1.7Hz,1H),7.63(d,J=5.9Hz,2H),7.5 5(t,J=7.7Hz,1H),7.30(d,J=7.8Hz,1H),7.09(d,J=7.6Hz,1H),6.41(d,J=4.8Hz,1H),5.77(s,1H),5.14–5.06(m , 1H), 4.81 (dd, J = 15.2, 7.0 Hz, 1H), 4.74–4.63 (m, 1H), 4.53 (s, 2H), 4.47–4.30 (m, 2H), 3.09 (s, 1H), 2.94 (s, 1H), 2.76–2.59 (m, 2H), 2.48 (s, 1H), 2.34–2.13 (m, 1H), 1.85 (s, 4H), 1.49 (s, 1H), 1.34 (s, 1H), 1.24 (d, J = 4.3 Hz, 3H). HRMS (ESI): calculated value C 32 H 34 FN 7 O 5 SSe,[M+H] + 712.1542, found 712.1582. HPLC: t R =3.60min, purity 94.67%.
[0234] Example 15 Preparation of Compound 15
[0235] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-N-(methylcarbamoyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-cyclopropylsulfonylurea (Compound 15)
[0236]
[0237] Compound 15 was synthesized from cyclopropylcarbamic acid phenyl ester and intermediate 14-7 according to the synthetic route of compound 14. Compound 15 was a white solid, 62 mg in total, with a yield of 66.2%. 1 H NMR (300 MHz, DMSO-d 6)δ10.71(s,1H),8.39–8.29(m,1H),7.98–7.74(m,3H),7.72–7.56(m,3H),7.36(d,J=7.9Hz,1H),7. 13(d,J=7.5Hz,1H),7.02–6.96(m,1H),5.77(s,1H),5.04(d,J=7.0Hz,1H),4.89(s,2H),4.75(d,J=1 5.2Hz, 1H), 4.59–4.43 (m, 2H), 4.36 (d, J=8.6Hz, 1H), 3.83 (s, 2H), 3.04 (s, 1H), 2.74 (s, 1H), 2.37 (d, J=7.4Hz, 2H), 2.34–2.11 (m, 3H), 1.55–1.45 (m, 1H), 1.37–1.22 (m, 1H), 1.24 (s, 5H), 0.85 (m, 1H). HRMS (ESI): calculated value C 34 H 36 FN 7 O 4 SSe,[M+H] + 738.1771, found 738.1735. HPLC t R =4.21min, purity 99.25%.
[0238] Example 16 Preparation of Compound 16
[0239] (S)-2-((4-(6-((2-fluoro-4-(trifluoromethyl)benzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 16)
[0240]
[0241] Compound 16 was synthesized using 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 16 was a white solid, 28.4 mg in total, with a yield of 59.9%. 1 H NMR (300 MHz, DMSO-d 6)δ8.28(s,1H),7.82(d,J=8.4Hz,1H),7.78–7.54(m,2H),7.51(dd,J=11.8,7.9Hz,4H),7.32(dd,J=17.3,7.8Hz,1H),7.09(dd ,J=7.7,5.0Hz,1H),5.11(dd,J=7.2,2.8Hz,1H),4.81(dd,J=15.2,7.1Hz,1H),4.66(dd,J=15.1,3.0Hz,1H),4.54(d,J=3.5Hz , 3H), 4.49–4.30 (m, 1H), 4.11–3.93 (m, 1H), 3.81 (d, J = 13.4 Hz, 1H), 3.44–3.34 (m, 1H), 3.33–3.14 (m, 1H), 2.94–2.83 (m, 1H), 2.79–2.59 (m, 1H), 2.49–2.36 (m, 1H), 2.35–2.14 (m, 1H), 2.09–1.96 (m, 2H), 1.87 (dd, J = 11.2, 5.0 Hz, 2H), 1.85–1.66 (m, 1H). HRMS (ESI): calculated value C 31 H 30 F 4 N 4 O 3 Se,[M+H] + 663.1492, found 663.1467. HPLC t R =4.17min, purity 95.77%.
[0242] Example 17 Preparation of Compound 17
[0243] (S)-2-((4-(6-((4-cyano-2-methoxybenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 17)
[0244]
[0245] Compound 17 was synthesized using 4-(bromomethyl)-3-methoxybenzonitrile and intermediate 1-6 as starting materials according to the synthetic route of compound 1. Compound 17 was a white solid, 42.3 mg in total, with a yield of 59.8%. 1 H NMR (300 MHz, DMSO-d 6)δ12.79(s,1H),8.27(s,1H),7.81(d,J=8.4Hz,1H),7.65(d,J=8.4Hz,1H),7.48(dd,J=14.3,6.7Hz,2H),7.28(dd,J=19 .4,7.8Hz,2H),7.05(d,J=7.6Hz,1H),5.11(h,J=6.1Hz,1H),4.80(dd,J=15.2,7.1Hz,1H),4.65(dd,J=15.2,2.9Hz,1H), 4.43 (s, 2H), 4.48–4.37 (m, 1H), 4.35 (dd, J = 10.4, 4.9 Hz, 1H), 3.98 (d, J = 13.5 Hz, 1H), 3.84 (d, J = 10.4 Hz, 4H), 3.05 (d, J = 11.1 Hz, 1H), 2.91 (d, J = 11.2 Hz, 1H), 2.79–2.59 (m, 2H), 2.43 (s, 1H), 2.35–2.15 (m, 2H), 1.81 (dd, J = 23.9, 11.7 Hz, 4H). HRMS (ESI): calculated value C 32 H 33 N 5 O 4 Se,[M+H] + 632.1771, found 632.1757. HPLC t R =7.88min, purity 94.36%.
[0246] Example 18 Preparation of Compound 18
[0247] 2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 18)
[0248]
[0249] Compound 18 was prepared using starting material 18-1 according to the following route.
[0250]
[0251] Step 1: Preparation of methyl 3-((2-methoxyethyl)amino)-4-nitrobenzoate (18-3)
[0252] Compound 18-1 (1.90 g, 9.54 mmol) was dissolved in 20 mL ACN, and compound 18-2 (1.00 mL, 11.45 mmol) and DIPEA (3.32 mL, 19.08 mmol) were added, and the mixture was heated to 60 °C and stirred for 8 h. After the reaction was completed by TLC detection, the mixture was extracted with water and EA, and the organic phases were combined. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system: PE:EA=70:1, v / v) gave a yellow solid 18-3 (1.72 g, yield 70.26%). 1 H NMR (300MHz, DMSO-d6) δ8.18(dd,J=9.1,4.1Hz,2H),7.57(d,J=1.7Hz,1H),7.15(dd,J=8.9,1.8Hz,1H),3.89(s,3H),3.66–3.50(m,4H),3.34(s,3H). LC-MS:[M+H] + =255.1.
[0253] Step 2: Preparation of methyl 4-amino-3-((2-methoxyethyl)amino)benzoate (18-4)
[0254] The intermediate 18-3 (1.72 g, 6.69 mmol) was dissolved in 20 mL THF, 10% Pd / C (170 mg) was added, and stirred at room temperature for 2 h under hydrogen protection. After the reaction was completed by TLC detection, the reaction solution was filtered through diatomaceous earth, washed with DCM, and the filtrate was concentrated under reduced pressure. Purification by column chromatography (elution system PE: EA = 10: 1, v / v) gave a colorless oily liquid 18-4 (1.32 g, yield 86.73%).
[0255] 1 H NMR (300 MHz, DMSO-d 6 )δ7.17(dd,J=8.1,1.9Hz,1H),6.99(d,J=1.9Hz,1H),6.56(d,J=8.1Hz,1H),5.46(s,2H),4. 65(t,J=5.5Hz,1H),3.73(s,3H),3.56(t,J=5.6Hz,2H),3.30(s,3H),3.22(q,J=5.6Hz,2H). LC-MS:[M+H] + =225.1.
[0256] Step 3: Preparation of methyl 2-(chloromethyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylate (18-5)
[0257] Intermediate 18-4 (1.32 g, 5.80 mmol) was dissolved in 20 mL ACN and p-TSA·H 2 O (220.02 mg, 1.16 mmol) and 2-chloro-1,1,1-trimethoxyethane (1.56 mL, 11.60 mmol), heated to 60 ° C and stirred for 4 h. After the reaction was completed by TLC detection, it was extracted with water and EA, the organic phase was combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system PE: EA = 20: 1, v / v) gave a colorless oily liquid (989.27 mg, yield 59.97%).
[0258] 1 H NMR (300 MHz, DMSO-d 6 )δ8.29(dd,J=1.7,0.7Hz,1H),7.87(dd,J=8.5,1.6Hz,1H),7.73(dd,J=8.5,0.6Hz,1H ), 5.10 (s, 2H), 4.61 (t, J = 5.1Hz, 2H), 3.90 (s, 3H), 3.70 (t, J = 5.1Hz, 2H), 3.21 (s, 3H). LC-MS:[M+H] + =283.1.
[0259] Step 4: Preparation of methyl 2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylate (18-6)
[0260] Using intermediate 18-5 and intermediate 1-6 as raw materials, a white solid 18-6 (307 mg, yield 66.8%) was obtained using the synthetic route of compound 1.
[0261] Step 5: Preparation of 2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 18)
[0262] Compound 18 was synthesized from intermediate 18-6 according to the synthetic route of compound 1. Compound 18 was a white solid, 265.28 mg in total, with a yield of 66.1%. 1 H NMR (300 MHz, DMSO-d 6)δ12.81(s,1H),8.19(s,1H),7.81(d,J=8.7Hz,2H),7.68–7.58(m,3H),7.52(d,J=9.9Hz,1H),7.28(d,J=7.9Hz,1H),7.07(d,J=7.4Hz ,1H),4.62(s,2H),4.50(s,2H),3.87(s,2H),3.75(s,2H),3.52(s,1H),2.95(d,J=10.6Hz,2H),2.71(s,1H),2.24(s,2H),1.82(s,5H). HRMS(ESI): calculated value C 30 H 30 FN 5 O 3 Se,[M+H] + 608.1571, found 608.1551; HPLC t R =5.85min, purity 97.32%.
[0263] Example 19 Preparation of Compound 19
[0264] 2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(tetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 19)
[0265]
[0266] Compound 19 was synthesized using 3-aminotetrahydrofuran and compound 18-1 as starting materials according to the synthetic route of compound 18. Compound 19 was a white solid, with a total of 193.39 mg and a yield of 72.5%. 1 H NMR (300 MHz, DMSO-d 6)δ12.79(s,1H),8.34(s,1H),7.81(d,J=9.1Hz,2H),7.71–7.48(m,4H),7.28(d,J=7.8Hz,1H), 7.07(d,J=7.5Hz,1H),5.67(s,1H),4.52(s,2H),4.28–4.17(m,1H),4.11(dd,J=10.5,3.0Hz,1H ), 4.02–3.89 (m, 2H), 3.84 (d, J = 13.4 Hz, 1H), 3.64 (q, J = 8.7 Hz, 1H), 2.95 (d, J = 10.9 Hz, 1H), 2.84 (d, J = 10.9 Hz, 1H), 2.71 (s, 1H), 2.20 (q, J = 11.9 Hz, 3H), 1.82 (s, 3H), 1.74 (d, J = 11.7 Hz, 2H). HRMS (ESI): calculated value C 31 H 30 FN 5 O 3 Se,[M+H] + 620.1571, found 620.1551. HPLC t R =4.16min, purity 97.96%.
[0267] Example 20 Preparation of Compound 20
[0268] 2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 20)
[0269]
[0270] Compound 20 was synthesized using (1-ethyl-1H-imidazol-5-yl)methylamine and compound 18-1 as starting materials according to the synthetic route of compound 18. Compound 20 was a white solid, with a total of 64.92 mg and a yield of 49.3%. 1 H NMR (300 MHz, DMSO-d 6)δ12.70(s,1H),8.07(s,1H),7.86–7.76(m,3H),7.72–7.48(m,4H),7.28(d,J=7.8Hz,1H),7.02(d,J=7.6Hz,1H),6.44(s,1H),4.50(s,2H),4.07–3.92(m,2H),3.84(s,2H),3.27(t,J=6.0Hz,3H),3.24–3.13(m,3H),2.92(d,J=10.9Hz,2H),2.18(m,2H),1.88(dd,J=12.0,6.0Hz,4H). HRMS(ESI):calculated value C 31 H 30 FN 5 O 3 Se,[M+H] + 658.1839, measured value 658.1834. HPLCt R =7.92min, purity 94.66%.
[0271] Example 21 Preparation of Compound 21
[0272] 2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 21)
[0273]
[0274] Compound 21 was synthesized using thiazole-5-methylamine and compound 18-1 as starting materials according to the synthetic route of compound 18. Compound 21 was a white solid, 58.72 mg in total, with a yield of 55.6%. 1 H NMR (300 MHz, DMSO-d 6 )δ8.86(s,1H),8.10(s,1H),7.96(s,1H),7.80–7.67(m,2H),7.60(d,J=8.4Hz,1H),7.52(s,1H),7.47(t,J=7.7Hz,2H),7.21(d,J=7.8Hz,1H),6.98(d,J=7.6Hz,1H),5.90(s,2H),4.44(s,2H),3.83(s,2H),2.94(d,J=10.9Hz,2H),2.63(m,1H),2.18(m,2H),1.73(s,3H),1.73–1.59(m,1H). HRMS(ESI): calculated value C 31 H 27 FN 6O 2 SSe,[M+H] + 646.1138, found 646.1132. HPLC t R =4.81min, purity 97.65%.
[0275] Example 22 Preparation of Compound 22
[0276] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)-5,6-dihydro-1,2,4-triazin-1(4H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 22)
[0277]
[0278] Compound 22 was prepared using starting material 22-1 according to the following route.
[0279]
[0280] Step 1: Preparation of tert-butyl (6-bromopyridin-2-yl)carbamate (22-3)
[0281] Compound 22-1 (10.00 g, 36.76 mmol) was dissolved in 150 mL DMF and Cs 2 CO 3 (35.91g, 110.29mmol), stirred at room temperature for 0.5h, added compound 22-2 (9.50mL, 110.29mmol), heated to 70℃ and stirred for 3h. After the reaction was completed by TLC detection, it was extracted with water and EA, the organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system PE:EA=200:1, v / v) gave a colorless oily liquid 22-3 (10.51g, yield 91.25%).
[0282] 1 H NMR (300 MHz, DMSO-d 6 )δ7.77–7.63(m,2H),7.36(dd,J=6.3,2.0Hz,1H),5.98–5.79(m,1H),5.17–5.03(m,2H),4.43(dt,J=5.4,1.6Hz,2H),1.46(s,9H). LC-MS:[M+H] + =313.1.
[0283] Step 2: Preparation of tert-butyl (6-bromopyridin-2-yl)(2-oxoethyl)carbamate (22-4)
[0284] Intermediate 22-3 (10.51 g, 33.52 mmol) was dissolved in 200 mL THF:H 2 O=1:1 (v / v) mixed solution, potassium osmate dihydrate (105.05 mg, 0.33 mmol) and NaIO 4 (36.25 g, 167.62 mmol), stirred at room temperature for 1 h, a large amount of white solid precipitated from the reaction. After the reaction was completed by TLC detection, saturated sodium thiosulfate aqueous solution was poured into it, stirred for 10 min and extracted with EA, the organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system PE: EA = 100: 1, v / v) gave a colorless oily liquid 22-4 (9.75 g, yield 92.65%). 1 H NMR (300 MHz, DMSO-d 6 )δ9.63(s,1H),7.82(d,J=8.2Hz,1H),7.74(t,J=7.9Hz,1H),7.37(d,J=7.4Hz,1H),4.68(s,2H),1.45(s,9H). LC-MS:[M+H] + =315.1.
[0285] Step 3: Preparation of tert-butyl 2-(2-((6-bromopyridin-2-yl)(tert-butoxycarbonyl)amino)ethyl)hydrazine-1-carboxylate (22-6)
[0286] Intermediate 22-4 (9.75 g, 30.94 mmol) was dissolved in 150.00 mL DCE, compound 22-5 (8.23 g, 61.87 mmol) was added, and stirred at room temperature for 1 h. After the reaction was completed by TLC, NaBH 3 CN (5.84 g, 92.81 mmol,) and NaBH(OAc) 3 (19.78 g, 92.81 mmol), stirred at room temperature for about 3 h, and then treated with saturated NaHCO 3 After the reaction was quenched with aqueous solution, it was extracted with DCM, the organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system PE:EA=10:1, v / v) gave a colorless oily liquid (6.86 g, yield 50.79%). 1 H NMR (300 MHz, DMSO-d 6)δ8.13(s,1H),7.76–7.66(m,1H),7.62(dd,J=8.2,0.9Hz,1H),7.37(dd,J=7.5,0.9Hz,1 H), 4.58 (s, 1H), 3.83 (t, J = 7.2Hz, 2H), 2.87 (t, J = 7.2Hz, 2H), 1.46 (s, 9H), 1.38 (s, 9H). LC-MS:[M+H] + =431.1.
[0287] Step 4: Preparation of 6-bromo-N-(2-hydrazineethyl)pyridin-2-amine (22-7)
[0288] Dissolve the intermediate 22-6 (6.86 g, 15.76 mmol) in 120 mL DCM, add 60 mL of 4 M hydrogen chloride in dioxane solution, stir at room temperature for about 5 h, a large amount of white solid precipitates, after TLC detection, directly evaporate the solvent under reduced pressure, and the hydrochloride obtained is directly used for the next step without purification. LC-MS: [M+H] + =231.1.
[0289] Step 5: Preparation of 6-bromo-N-(2-hydrazineethyl)pyridin-2-amine (22-8)
[0290] Dissolve the hydrochloride of the product from the previous step in 80 mL of glacial acetic acid, add 40 mL of trimethyl orthoformate, N 2 After the reaction was completed by TLC, the solvent was evaporated and saturated NaHCO 3 The aqueous solution was extracted with EA, the organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system PE:EA=2:1, v / v) gave a white solid 22-8 (4.18 g, yield 91.85%). 1 H NMR (300 MHz, DMSO-d 6 )δ8.49(s,1H),7.87(d,J=13.9Hz,1H),7.72(m,1H),7.27(m,2H),3.94–3.80(m,2H),3.85(s,2H). LC-MS:[M+H] + =268.9.
[0291] Step 6: Preparation of 4-(6-bromopyridin-2-yl)-1,4,5,6-tetrahydro-1,2,4-triazine (22-9)
[0292] Intermediate 22-8 (4.18 g, 15.29 mmol) was dissolved in 100 mL of a mixed solution of DCM:MeOH = 1:1 (v / v), and 15.28 mL of a 4 M aqueous hydrochloric acid solution was added dropwise under an ice bath (0°C), and stirred at room temperature overnight. After the reaction was completed by TLC, a large amount of saturated NaHCO 3 The aqueous solution was extracted with DCM, the organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system: PE:EA=1:2, v / v) gave a yellow solid 22-9 (1.62 g, yield 43.67%). 1 H NMR (300 MHz, DMSO-d 6 )δ7.75(s,1H),7.62(t,J=8.0Hz,1H),7.08(dd,J=16.4,7.9Hz,2H),6.35(s,1H),3.73(t,J=5.0Hz,2H),3.12(t,J=5.1Hz,2H). LC-MS:[M+H] + =241.0.
[0293] Step 7: Preparation of tert-butyl 4-(6-bromopyridin-2-yl)-5,6-dihydro-1,2,4-triazine-1(4H)-carboxylate (22-10)
[0294] Intermediate 22-9 (1.62 g, 6.66 mmol) was dissolved in 30 mL DCM, and DMAP (81.42 mg, 0.66 mmol), TEA (1.15 mL, 8.00 mmol) and Boc 2 O (3.18 mL, 13.32 mmol), stirred at room temperature overnight. After the reaction was completed by TLC, it was extracted with water and DCM, the organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (elution system PE: EA = 4: 1, v / v) gave a white solid 22-10 (780.03 mg, yield 34.47%).
[0295] 1 H NMR (300 MHz, DMSO-d 6 )δ7.80(s,1H),7.70(t,J=7.9Hz,1H),7.22(dd,J=8.0,5.1Hz,2H),3.82(tt,J=4.6,2.7Hz,4H),1.46(s,9H). LC-MS:[M+H] + =341.0.
[0296] Step 8: Preparation of (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)-5,6-dihydro-1,2,4-triazin-1(4H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 22)
[0297] Compound 22 was synthesized from intermediate 22-10 according to the synthetic route of compound 1. Compound 22 was a white solid, 45.84 mg in total, with a yield of 75.2%. 1 H NMR (300 MHz, DMSO-d 6 )δ12.77(s,1H),8.28(s,1H),7.95(s,1H),7.84–7.77(m,2H),7.68–7.51(m,4H),7.02(d,J=7.5Hz,1H),6.84(d,J=8.3Hz,1H),5.10–5.01(m,1H),4.83(dd,J=15.5,7.1Hz,1H),4.70(d,J=14.1Hz,1H),4.56–4.30(m,6H),3.85(s,2H),3.14(d,J=5.2Hz,2H),2.69(dd,J=16.5,4.7Hz,1H),2.39(t,J=9.4Hz,1H). HRMS(ESI): calculated value C 29 H 26 FN 7 O 3 Se,[M+H] + 620.1319, found 620.1325. HPLC t R =4.50min, purity 98.18%.
[0298] Example 23 Preparation of Compound 23
[0299] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 23)
[0300]
[0301] Compound 23 was synthesized from methyl 3,5-difluoro-4-nitrobenzoate and (S)-oxetane-2-methylamine according to the synthetic route of compound 18. Compound 23 was a white solid, 52.25 mg in total, with a yield of 60.8%. 1 H NMR (300 MHz, DMSO-d 6)δ13.07(s,1H),8.15(s,1H),7.81(d,J=9.9Hz,1H),7.67–7.46(m,4H),7.29(d,J=7.8Hz, 1H),7.08(d,J=7.6Hz,1H),5.15–5.06(m,1H),4.84(d,J=16.0Hz,1H),4.68(d,J=14.8Hz,1 H), 4.52 (s, 2H), 4.39 (q, J = 8.2 Hz, 3H), 3.99 (d, J = 13.8 Hz, 1H), 3.81 (d, J = 13.8 Hz, 1H), 3.03 (d, J = 10.1 Hz, 1H), 2.88 (d, J = 11.1 Hz, 1H), 2.69 (s, 3H), 2.26 (s, 1H), 1.82–1.77 (m, 4H). HRMS (ESI): calculated value C 31 H 29 F 2 N 5 O 3 Se,[M+H] + 638.1476, found 628.1463. HPLC t R =4.36min, purity 98.19%.
[0302] Example 24 Preparation of Compound 24
[0303] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)seleno)pyridin-2-yl)-5,6-dihydro-1,2,4-triazine-1(4H)-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 24)
[0304]
[0305] Compound 24 was synthesized from intermediate 22-10, intermediate 1-7 and methyl 3,5-difluoro-4-nitrobenzoate according to the synthetic route of compound 22. Compound 24 was a white solid, 39.82 mg in total, with a yield of 57.9%. 1 H NMR (300 MHz, DMSO-d 6)δ13.11(s,1H),8.17(s,1H),7.96(s,1H),7.81(d,J=10.0Hz,1H),7.63–7.47(m,4H),7.03(d,J=7.6Hz,1H),6.84(d,J=8.0Hz,1H),5.07(d,J=8.2Hz,1H),4.88(d,J=15.1Hz,1H),4.73(d,J=15.2Hz,1H),4.47(t,J=10.8Hz,5H),4.37(s,1H),3.86(s,2H),3.17(s,2H),2.69(s,1H),2.39(s,1H). HRMS(ESI): calculated value C 29 H 25 F 2 N 7 O 3 Se,[M+H] + 638.1225, found 638.1236. HPLC t R =5.84min, purity 96.71%.
[0306] Example 25 Preparation of Compound 25
[0307] (S)-4-Fluoro-2-((4-(6-((2-methoxy-4-(trifluoromethyl)benzyl)seleno)pyridin-2-yl)-5,6-dihydro-1,2,4-triazin-1(4H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 25)
[0308]
[0309] Compound 25 was synthesized from intermediate 22-10, 2-methoxy-4-(trifluoromethyl)benzyl bromide and methyl 3,5-difluoro-4-nitrobenzoate according to the synthetic route of compound 22. Compound 25 was a white solid, 45.07 mg in total, with a yield of 60.4%.
[0310] 1 H NMR (300 MHz, DMSO-d 6)δ13.11(s,1H),8.18(s,1H),7.98(s,1H),7.58–7.44(m,3H),7.27–7.16(m,2H), 7.00(d,J=7.6Hz,1H),6.84(dd,J=14.7,8.4Hz,1H),5.07(d,J=6.9Hz,1H),4.88( dd, J = 15.5, 7.0 Hz, 1H), 4.80–4.68 (m, 1H), 4.59–4.28 (m, 6H), 3.88 (s, 5H), 3.37 (s, 1H), 3.17 (d, J = 6.5 Hz, 1H), 2.67 (d, J = 8.6 Hz, 1H), 2.41 (dd, J = 16.7, 8.0 Hz, 1H). HRMS (ESI): calculated value C 30 H 28 F 4 N 6 O 4 Se,[M+H] + 693.1346, found 693.1344. HPLC t R =4.81min, purity 98.68%.
[0311] Example 26 Preparation of Compound 26
[0312] (S)-2-((4-(6-((4-cyano-2-methoxybenzyl)seleno)pyridin-2-yl)-5,6-dihydro-1,2,4-triazine-1(4H)-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 26)
[0313]
[0314] Compound 26 was synthesized from intermediate 22-10, 4-(bromomethyl)-3-methoxybenzonitrile and methyl 3,5-difluoro-4-nitrobenzoate according to the synthetic route of compound 22. Compound 26 was a white solid, 43.73 mg in total, with a yield of 67.4%. 1 H NMR (300 MHz, DMSO-d 6)δ13.12(s,1H),8.17(s,1H),7.97(s,1H),7.52(dd,J=9.6,6.4Hz,2H),7.44(d,J=6.1Hz,2H ),7.31(d,J=7.8Hz,1H),7.00(d,J=7.5Hz,1H),6.81(d,J=8.3Hz,1H),5.07(d,J=8.6Hz,1H) ,4.88 (dd, J = 15.5, 6.9 Hz, 1H), 4.74 (d, J = 15.1 Hz, 1H), 4.50 (dd, J = 22.7, 13.9 Hz, 3H), 4.39 (s, 3H), 3.87 (d, J = 7.8 Hz, 5H), 3.36 (s, 1H), 2.69 (s, 1H), 2.51 (s, 2H), 2.41 (d, J = 10.0 Hz, 1H). HRMS (ESI): calculated value C 30 H 28 FN 7 O 4 Se,[M+H] + 650.1425, found 650.1432. HPLC t R =4.13min, purity 99.00%.
[0315] Example 27 Preparation of Compound 27
[0316] (S)-4-Fluoro-2-((4-(6-((2-fluoro-4-(trifluoromethyl)benzyl)seleno)pyridin-2-yl)-5,6-dihydro-1,2,4-triazin-1(4H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 27)
[0317]
[0318] Compound 27 was synthesized from intermediate 22-10, 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene and methyl 3,5-difluoro-4-nitrobenzoate according to the synthetic route of compound 22. Compound 27 was a white solid, 37.46 mg in total, with a yield of 59.8%.
[0319] 1 H NMR (300 MHz, DMSO-d 6)δ13.14(s,1H),δ8.16(s,1H),7.97(s,1H),7.63(d,J=9.0Hz,2H),7.56(d,J=8.6Hz,1H),7. 50(dd,J=7.4,2.8Hz,2H),7.03(d,J=7.5Hz,1H),6.84(d,J=8.3Hz,1H),5.06(d,J=7.6Hz,1H ), 4.86 (dd, J = 15.4, 7.0 Hz, 1H), 4.73 (d, J = 14.9 Hz, 1H), 4.58–4.35 (m, 5H), 4.39–4.28 (m, 1H), 3.86 (t, J = 4.9 Hz, 2H), 3.16 (q, J = 5.7 Hz, 2H), 2.67 (d, J = 8.8 Hz, 1H), 2.39 (t, J = 8.6 Hz, 1H). HRMS (ESI): calculated value C 29 H 25 F 5 N 6 O 3 Se,[M+H] + 681.1146, found 681.1154. HPLC t R =4.51min, purity 98.96%.
[0320] Example 28 Preparation of Compound 28
[0321] (S)-2-((4-(6-((4-chloro-2-fluorobenzyl)seleno)pyridin-2-yl)-5,6-dihydro-1,2,4-triazin-1(4H)-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 28)
[0322]
[0323] Compound 28 was synthesized from intermediate 22-10, 1-(bromomethyl)-4-chloro-2-fluorobenzene and methyl 3,5-difluoro-4-nitrobenzoate according to the synthetic route of compound 22. Compound 28 was a white solid, 39.03 mg in total, with a yield of 56.6%.
[0324] 1 H NMR (300 MHz, DMSO-d 6)δ13.11(s,1H),8.17(s,1H),7.97(s,1H),7.55(d,J=6.8Hz,2H),7.52–7.33(m,2H), 7.19(d,J=8.3Hz,1H),7.02(d,J=7.6Hz,1H),6.83(d,J=8.3Hz,1H),5.11–5.02(m,1H ), 4.87 (dd, J = 15.2, 7.0 Hz, 1H), 4.73 (d, J = 15.0 Hz, 1H), 4.58–4.30 (m, 2H), 4.37 (s, 4H), 3.86 (s, 2H), 3.16 (d, J = 6.2 Hz, 2H), 2.70 (d, J = 11.6 Hz, 1H), 2.39 (t, J = 8.6 Hz, 1H). HRMS (ESI): calculated value C 28 H 25 CIF 2 N 6 O 3 Se,[M+H] + 647.0883, found 647.0883. HPLC t R =4.83min, purity 97.94%.
[0325] Example 29 Evaluation of GLP-1R-cAMP agonist effect
[0326] The present invention uses a cAMP signal agonist effect detection method to characterize the agonist activity of a compound on GLP-1R.
[0327] (1) Experimental reagents and instruments (see Table 2 and Table 3)
[0328] Table 2 Experimental reagents and consumables
[0329]
[0330] Table 3 Experimental instruments and devices
[0331]
[0332]
[0333] (2) Experimental cells
[0334] In the present invention, we used a HEK cell line that stably expresses GLP-1R (constructed by Beijing Aisiyipu Biotechnology Co., Ltd., expressing the human GLP-1R gene), and the number of cells used for testing was 1000 / well. The cell lines were cultured in DMEM + 100μg / mL Hygromycin B medium containing 10% fetal bovine serum, the culture temperature was 37°C, and the carbon dioxide concentration was 5%. The old culture medium was removed and washed once with PBS, and then 1mL TrypLE TM Express solution (Beijing Aisiyipu Biotechnology Co., Ltd.), incubate at 37℃ for about 2 minutes. When the cells detach from the bottom of the dish, add about 2mL of complete medium DMEM preheated at 37℃. Gently blow the cell suspension with a pipette to separate the aggregated cells. Transfer the cell suspension to a sterile centrifuge tube, centrifuge at 1000rpm for 5 minutes to collect the cells for experiments or subculture. To maintain the physiological activity of the cells, the experimental cell fusion degree is controlled at about 80%. Cell passaging, recovery and freezing are carried out according to conventional methods. All operations follow the standard operating procedures for cell culture of Beijing Aisiyipu Biotechnology Co., Ltd.
[0335] (3) Experimental methods
[0336] The test was performed using the LANCE Ultra cAMP kit.
[0337] The kit contains: Stimulation Buffer, Eu-cAMP, Detection buffer, and ULight-anti-cAMP.
[0338] Step 1: All reagents in the kit should be equilibrated to room temperature before use. Prepare 1× Stimulation Buffer according to the kit instructions.
[0339] Step 2: The compound to be tested was diluted with DMSO in a gradient manner, and then diluted to 10× with 1×Stimulation Buffer. The actual starting test concentration was set to 5000nM, and 10 groups were diluted in a 5-fold gradient, where each test group contained 2 sets of duplicate test wells. Each test group was set with a DMSO concentration of 0.1% as the negative control group, and a GLP-1 (7-37) concentration of 100nM (provided by Beijing Aisiyipu Biotechnology Co., Ltd.) as the positive control group.
[0340] Step 3: Stably transfected cells were cultured to 80% confluence; cells were collected by trypsin digestion and counted, and then inoculated into 384-well plates at 9 μL / well.
[0341] Step 4: Take 1 μL of the 10× compound diluted in step 2 and add it to the corresponding experimental well. After centrifugation, incubate at 37°C for 30 min.
[0342] Step 5: Dilute Eu-cAMP to the working concentration with detection buffer and add 5 μL / well to the corresponding experimental wells.
[0343] Step 6: Dilute ULight-anti-cAMP to the working concentration with detection buffer, then add 5 μL / well to the corresponding experimental wells; centrifuge and incubate at room temperature for 1 hour.
[0344] Step 7: After incubation, use the Biotek multifunctional microplate reader to detect the readings at 665nm and 620nm. Calculate the ratio of the readings at the corresponding wavelength conditions, R 665 / 620 , calculate the average ratio (R G roup), positive reference average ratio The average ratio of negative reference The excitation rate A was calculated according to the formula, and the excitation effect of the compound at the 5000nM level was determined. The compound with excitation effect (A 5000nM >50.00%). The A of the compound test concentration with an agonistic effect greater than 80% was selected and plotted against the corresponding concentration. The curve fitting and half agonist activity concentration (EC) were calculated using the nonlinear regression method of GraphPad Prism software. 50 )calculate.
[0345] (4) Calculation method
[0346]
[0347] The calculation result shall be rounded to 4 significant figures.
[0348] (5) Experimental results (see Table 4 and Table 5)
[0349] Reference drug Danuglipron (PF-06882961): synthesized with reference to patent WO2018109607A1.
[0350] Table 4 cAMP agonistic effect of 5000nM compounds
[0351]
[0352]
[0353] Table 5 EC of compounds for agonism of cAMP signal 50
[0354]
[0355]
[0356] The test results show that the compounds of the present invention can activate the downstream signal transduction of GLP-1R by stimulating the cAMP signaling pathway, and have a complete GLP-1R agonist effect and a low half-agonist concentration.
[0357] Example 30 Rat liver microsome stability test
[0358] The present invention uses LC-MS / MS method to detect the rat liver microsome stability of compound 1, compound 17 and compound 26 and PF-06882961.
[0359] (1)LC-MS / MS conditions
[0360] LC-MS / MS model: Shimadzu LCMS-8050;
[0361] Chromatographic column: GL Science ODS-3, 3μm, 2.1mm*50mm;
[0362] Mobile phase: binary high pressure gradient elution, 0-2min, pump A: methanol, 20%; pump B: water (containing 0.1% formic acid), 80%; 2-5min: pump A: methanol, 80%; pump B: water (containing 0.1% formic acid), 20%; 5-7min, pump A: methanol, 20%; pump B: water (containing 0.1% formic acid), 80%;
[0363] Detection wavelength: 254nm; detection time: 7min; injection volume: 5μL;
[0364] Calculation method: clarithromycin-internal standard method;
[0365] Internal standard concentration: 10 ng / mL;
[0366] (2) Establishment of standard curve
[0367] Prepare 100 mM MgCl 2 PBS solution, 5mM NADPH PBS solution, 5mg / mL rat liver microsomes (rHLM, purchased from Shanghai Quanyang Biotechnology Co., Ltd.) PBS diluted test solution (stored at 4°C), 5mg / mL inactivated rat liver microsomes (rHLM, inactivated by heating at 60°C for 1h) PBS diluted test solution (stored at 4°C), 1mM compound MeOH stock solution. The compound stock solution was diluted to 80μM test solution with PBS, and diluted ten groups with PBS in a two-fold gradient.
[0368] Test system: 120 μL PBS, 20 μL 5 mg / mL inactivated liver microsomes, 10 μL 100 mM MgCl 2 Solution, 10 μL compound, mix well, incubate at 37℃ for 5 min, add 40 μL NADPH solution. A total of 200 μL, rHLM in the test system was diluted 10 times, MgCl 2 Dilute 20-fold, compound dilute 20-fold, NADPH dilute 5-fold.
[0369] Take 10 μL of sample, add 30 μL of 12 ng / mL clarithromycin diluted in acetonitrile as internal standard, vortex mix, the final concentration of the compound detection is 80 times the concentration of the original solution, precipitate protein, centrifuge at 12000 rpm, 4 ° C for 5 minutes, take 20 μL of supernatant. The final concentration of the test falls between 1000 ng / mL-0.1 ng / mL, LC-MS / MS injection 5 μL detection, using the internal standard method, the concentration ratio (C) versus the area ratio (A) to draw a standard curve.
[0370] The standard curve formulas for compound 1 and PF-06882961 were prepared using the above test method. The fitting results showed that the peak area response of compound 1 and PF-06882961 in the range of 0.1 ng / mL-1000 ng / mL was linearly related to the concentration, and the fitting regression degree was good.
[0371] The standard curve of compound 1 is as follows Figure 1 As shown, the standard curve of PF-06882961 is as follows Figure 2 shown.
[0372] (3) Test method
[0373] The test method described in step (2) was used for detection, with three parallel groups. The test sample concentration was 4 μg / mL. The timing began after the addition of the NADPH solution to initiate the reaction, and samples were taken at 0, 5, 10, 15, 20, 30, 45, 60, 90, and 120 min. The residual concentration of the compound at each time point was calculated, and the compound retention percentage (HLM Remaining, %) was calculated with the compound concentration at 0 min as 100%. A straight line was fitted between the average of the natural logarithm of the retention percentage and the incubation time to obtain the elimination rate constant k (min -1 ) and SEM. Calculate the cleaning related parameters according to the following formula:
[0374] Half-life 1 / 2 (min) = 0.693 / |k|; intrinsic clearance CL int (mL / min / kg)=(0.693 / t 1 / 2 )*(1 / C rHLM )*scaling factor (rat: 1792);
[0375] The degradation of the compounds under rHLM conditions was 1 / 2 and CL int The stability of the compounds in rat liver microsomes was characterized. The results are shown in Table 6:
[0376] Table 6 rHLM stability of compounds
[0377]
[0378] The test results showed that the stability of compound 1, compound 17 and compound 26 in rat liver microsomes was better than that of the positive molecule PF-06882961 in rat liver microsomes.
[0379] Example 31 Pharmacokinetics Test
[0380] The present invention uses the LC-MS / MS method to calculate the resident concentrations (c) of compound 1 and PF-06882961 in adult rat plasma at different time points (t) under different administration conditions, draws the ct curves of corresponding conditions / corresponding compounds, and uses the Winnolin7.0 software non-modal model to fit and analyze the ct parameters.
[0381] (1) Preliminary preparation
[0382] Rats: SD strain, male, 6-8 weeks old, weight 180 g-220 g;
[0383] Administration: intravenous injection (1 mg / kg or 10 mg / kg); oral administration (5 mg / kg or 50 mg / kg);
[0384] Solvent preparation formula: 10% DMSO + 40% PEG-400 + 50% saline (containing 20% w / v hydroxypropyl-β-cyclodextrin), solution concentration is 1 mg / mL or 5 mg / mL;
[0385] (2)LC-MS / MS conditions
[0386] LC-MS / MS model: Shimadzu LCMS-8050;
[0387] Chromatographic column: GL Science ODS-3, 3μm, 2.1mm*50mm;
[0388] Mobile phase: binary high pressure gradient elution, 0-2min, pump A: methanol, 20%; pump B: water (containing 0.1% formic acid), 80%; 2-5min: pump A: methanol, 80%; pump B: water (containing 0.1% formic acid), 20%; 5-7min, pump A: methanol, 20%; pump B: water (containing 0.1% formic acid), 80%;
[0389] Detection wavelength: 254nm; Detection time: 7min; Injection volume: 10μL or 1μL;
[0390] Calculation method: clarithromycin-internal standard method;
[0391] Internal standard concentration: 10 ng / mL;
[0392] (3) Establishment of standard curve
[0393] Use chromatographic acetonitrile to prepare 10000ng / mL, 1000ng / mL, 500ng / mL, 200ng / mL, 100ng / mL, 50ng / mL, 10ng / mL, 1ng / mL, 0.1ng / mL standard concentration test samples of the test compound, take 20μL of the test sample, dilute it with 40μL of 20ng / ml acetonitrile solution and 20μL of blank rat plasma, analyze it according to the described LC-MS method, inject 10μL each time, and calculate the corresponding ion peak area. Use the internal standard method to draw the standard curve of the corresponding compound with concentration ratio (C) versus area ratio (A).
[0394] (4) Sampling and processing calculation
[0395] Rats were weighed and the dosing volume was calculated. Blood collection time points were set at 1min, 5min, 10min, 30min, 45min, 60min, 120min, 240min, 360min, 480min, 540min, and 1440min, for a total of 12 time points, and 4 parallel experimental groups were set for each dosing group. The timing started at the time point when the dosing was completed, and 100μL to 200μL of blood was collected from the orbital venous plexus of the rat at the set blood collection time point, and the plasma was separated according to the general plasma separation method (4500rpm, RT, 5min), and then 20μL of sample plasma was drawn. 40μL of 20ng / mL clarithromycin acetonitrile solution and 20μL of acetonitrile were added to the sample plasma, vortexed to mix, and protein was precipitated. Centrifuge at 12000 rpm, 4°C for 5 min, aspirate 40 μL of the supernatant, analyze according to the above LC-MS method, inject 10 μL of each sample, calculate the corresponding ion peak area, and use the internal standard method standard curve to calculate the compound concentration.
[0396] The CT curves of compound concentration versus time were plotted, and the pharmacokinetic parameters were calculated using Winnolin 7.0 software non-compartmental statistical moment method. Wherein the subscript iv represents intravenous injection, and po represents oral administration by gavage. max and T max All are measured values, AUC last The value is calculated by the trapezoidal area method, the area under the curve AUC for 0-+∞ time int_obs =AUC last +C last / HL_Lambda_z, where C last represents the final identifiable effective minimum concentration, and HL_Lambda_z represents the elimination phase half-life. Oral bioavailability F = (AUC int_obs p.o. / D p.o. ) / (AUC int_obs i.v. / D i.v. )*100%, where AUC represents the area under the curve and D represents the dosage.
[0397] (5) Test parameters
[0398] The ct curve of PF-06882961 is as follows Figure 3 As shown, the ct curve of the low-dose group of compound 1 is as follows Figure 4 As shown, the ct curve of the high-dose group of compound 1 is as follows Figure 5 The PK parameters obtained from the test are shown in Table 7.
[0399] Table 7 Pharmacokinetic parameters of the compounds
[0400]
[0401] *PF-06882961 is administered orally in the form of its Tris salt, which is synthesized by the synthesis method disclosed in patent WO2018109607A1;
[0402] **Oral Group V z_obs and CL obs The data show apparent parameters.
[0403] The data results show that the intravenous half-life of the low-dose group of compound 1 is short, the oral half-life is long, the drug clearance rate is fast under intravenous administration, and the plasma drug inventory is lower than that of the positive drug; under oral administration, the drug absorption and metabolic distribution are in balance, and the plasma drug inventory is significantly improved compared with the intravenous condition, showing the characteristics of tissue drug accumulation and sustained release, resulting in an oral bioavailability that is better than the positive drug PF-06882961, which is 20.84%. The half-life of the intravenous and oral conditions of the high-dose group is moderate, at 1.37h and 2.65h respectively; the in vivo absorption degree and average AUC value are higher than those of the positive drug, and the oral high-dose group has a higher bioavailability than PF-06882961.
[0404] The above experimental results evaluated the in vitro drug-forming properties of compound 1.
[0405] Example 32 Pharmacokinetics Test
[0406] The present invention uses the LC-MS / MS method to calculate the resident concentration (c) of compound 17 in adult rat plasma at different time points (t) under different administration conditions, draws the ct curve of corresponding conditions / corresponding compounds, and uses Winnolin7.0 software non-mode model to fit and analyze the ct parameters.
[0407] (1) Preliminary preparation
[0408] Rats: SD strain, male, 6-8 weeks old, weight 180 g-220 g;
[0409] Administration: intravenous injection (5 mg / kg); oral administration (30 mg / kg);
[0410] Prepare solvent formula: 10% DMSO + 40% PEG-400 + 50% saline (containing 20% w / v hydroxypropyl-β-cyclodextrin), solution concentration is 5 mg / mL;
[0411] (2)LC-MS / MS conditions
[0412] Same as Example 31.
[0413] (3) Establishment of standard curve
[0414] Same as Example 31.
[0415] (4) Sampling and processing calculation
[0416] Same as Example 31.
[0417] (5) Test parameters
[0418] The PK parameters obtained from the test are shown in Table 8.
[0419] Table 8 Pharmacokinetic parameters of the compounds
[0420]
[0421] The pharmacokinetic properties of compound 17 were evaluated under the conditions of intravenous injection of 5 mg / kg and oral gavage of 30 mg / kg. The experimental results showed that the intravenous and oral half-lives of compound 17 were moderate, the average plasma drug exposure, apparent distribution volume and clearance were relatively maintained, and the oral bioavailability reached 28.91%. The above experimental results evaluated the in vitro drug properties of compound 17.
[0422] So far, we have obtained GLP-1R small molecule agonists with good GLP-1R agonist activity and acceptable oral administration effect, which has expanded the application of selenium in drug design and synthesis. However, the structural design and modification of the selenium linker compound series represented by compound 1 and compound 17 is still relatively conservative, and there is still potential for further improvement in drug properties such as bioavailability and cardiotoxicity.
[0423] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph thereof: in, Ring A is selected from C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 5-12 Spirobicyclic, C 5-12 Spiroheterobicyclic group, C 5-12 Fused bicyclic group, C 5-12 Fused heterobicyclic group, C 5-12 Bridged ring or C 5-12 bridged heterocyclic group; L is selected from -C(O)-, -O-, -S-, -CR 4 R 5 or -NR 6 -; R 4 , R 5 are each independently selected from hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, -NR 5a R 5b , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group; the C1-C6 alkyl or C1-C6 alkoxy is optionally substituted by one or more of the following substituents: halogen, oxo, cyano, hydroxyl, C3-C6 saturated or partially saturated cycloalkyl; the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclic group is optionally substituted by one or more of the following substituents: halogen, oxo, cyano or -NR 5a R 5b ; R 5a , R 5b Each is independently selected from hydrogen or C1-C6 alkyl; R 6 Selected from hydrogen, C1-C6 alkyl, C3-C10 cycloalkyl, heterocyclic group, -S(O)2R 6a or -S(O)2N(R 6a )(NR 6b ); the cycloalkyl or heterocyclic group is optionally substituted by C1-C6 alkyl, -F or cyano; R 6a , R 6b Each is independently selected from -H, C1-C6 alkyl or C3-C10 cycloalkyl; R 1 C1-C6 alkyl substituted with 3-6 membered heterocyclyl, C1-C6 alkyl substituted with C3-C6 cycloalkyl, C1-C6 alkyl substituted with 5-8 membered heteroaryl, C1-C6 alkyl substituted with C1-C6 alkoxy, 3-6 membered heterocyclyl, C3-C6 cycloalkyl or 5-8 membered heteroaryl; the 3-6 membered heterocyclyl, C3-C6 cycloalkyl, 5-8 membered heteroaryl or C1-C6 alkoxy is optionally replaced by one of the following: substituted by one or more substituents: H, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, cyano, cyano-substituted C1-C6 alkyl, hydroxy, hydroxy-substituted C1-C6 alkyl, halo-substituted C1-C6 alkyl, halo-substituted C3-C6 cycloalkyl, halo-substituted C1-C6 alkoxy, halo-substituted C1-C6 alkylamino, acyl, amide, aminoacyl, sulfonyl or amino; R 2 Each is independently selected from a hydrogen atom, deuterium, halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C1-C6 alkoxy, amino, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group; R 3 Each is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; X 1 , X 2 , X 3 and X 4 The same or different, and each independently selected from -CR 7 or N atoms; R 7 is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl or heteroaryl; G is selected from G1 or G2; the structural formulas of G1 and G2 are as follows: Ring B and Ring C are each independently selected from a 6-12 membered aryl group or a 6-12 membered heteroaryl group; Y and Z are each independently selected from -CH2-, -S-, -SO-, -SO2-, -(O=S=NH)-, -Se- or -Se(O)-; R 8 , R 11 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl being optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; R 9 , R 10 , R 12 , R 13 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl; EE is selected from -COOH or a carboxyl surrogate; the carboxyl surrogate is selected from: m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; o is 0, 1, 2, 3, 4, or 5; p is 0, 1, 2, 3, 4 or 5.
2. The compound according to claim 1, characterized in that Ring A is selected from C 3-8 Cycloalkyl or C 2-9 Heterocyclic group; L is selected from -CR 4 R 5 ; R 1 Selected from C1-C6 alkyl substituted by 3-6 membered heterocyclyl, C1-C6 alkyl substituted by C3-C6 cycloalkyl, C1-C6 alkyl substituted by 5-8 membered heteroaryl, C1-C6 alkyl substituted by C1-C6 alkoxy; EE is selected from -COOH or a carboxyl surrogate.
3. The compound according to claim 2, characterized in that Ring A is selected from C 2-9 Heterocyclic group; Y and Z are each independently selected from -Se- or -Se(O)-; EE is selected from -COOH, 4. The compound according to claim 1, characterized in that Selected from:
5. A pharmaceutical composition, characterized in that: The invention comprises the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph thereof and a pharmaceutically acceptable carrier or excipient.
6. Use of the compound according to any one of claims 1 to 4 in the preparation of a GLP-1 receptor agonist, or in the preparation of a medicament for preventing and / or treating diseases associated with GLP-1 receptor stimulation.
7. The use according to claim 6, characterized in that The diseases associated with stimulating GLP-1 receptors include diabetes, diabetic complications, metabolic syndrome, obesity, non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, Parkinson's disease, Alzheimer's disease, hypertension, hyperlipidemia, atherosclerosis, cardiovascular risk, coronary heart disease or stroke.
8. A compound of formula II or a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph thereof: in, Ring A is selected from C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 5-12 Spirobicyclic, C 5-12 Spiroheterobicyclic group, C 5-12 Fused bicyclic group, C 5-12 Fused heterobicyclic group, C 5-12 Bridged ring or C 5-12 bridged heterocyclic group; L is selected from -C(O)-, -O-, -S-, -CR 4 R 5 or -NR 6 -; R 4 , R 5 are each independently selected from hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, -NR 5a R 5b , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group; the C1-C6 alkyl or C1-C6 alkoxy is optionally substituted by one or more of the following substituents: halogen, oxo, cyano, hydroxyl, C3-C6 saturated or partially saturated cycloalkyl; the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclic group is optionally substituted by one or more of the following substituents: halogen, oxo, cyano or -NR 5a R 5b ; R 5a , R 5b Each is independently selected from hydrogen or C1-C6 alkyl; R 6 Selected from hydrogen, C1-C6 alkyl, C3-C10 cycloalkyl, heterocyclic group, -S(O)2R 6a or -S(O)2N(R 6a )(NR 6b ); the cycloalkyl or heterocyclic group is optionally substituted by C1-C6 alkyl, -F or cyano; R 6a , R 6b Each is independently selected from -H, C1-C6 alkyl or C3-C10 cycloalkyl; R 1 C1-C6 alkyl substituted with 3-6 membered heterocyclyl, C1-C6 alkyl substituted with C3-C6 cycloalkyl, C1-C6 alkyl substituted with 5-8 membered heteroaryl, C1-C6 alkyl substituted with C1-C6 alkoxy, 3-6 membered heterocyclyl, C3-C6 cycloalkyl or 5-8 membered heteroaryl; the 3-6 membered heterocyclyl, C3-C6 cycloalkyl, 5-8 membered heteroaryl or C1-C6 alkoxy is optionally replaced by one of the following: substituted by one or more substituents: H, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, cyano, cyano-substituted C1-C6 alkyl, hydroxy, hydroxy-substituted C1-C6 alkyl, halo-substituted C1-C6 alkyl, halo-substituted C3-C6 cycloalkyl, halo-substituted C1-C6 alkoxy, halo-substituted C1-C6 alkylamino, acyl, amide, aminoacyl, sulfonyl or amino; R 2 Each is independently selected from a hydrogen atom, deuterium, halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C1-C6 alkoxy, amino, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl, 3-8 membered saturated or partially saturated heterocyclic group; R 3 Each is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; X 1 , X 2 , X 3 and X 4 The same or different, and each independently selected from -CR 7 or N atoms; R 7 is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl or heteroaryl; G is selected from G1 or G2; the structural formulas of G1 and G2 are as follows: Ring B and Ring C are each independently selected from a 6-12 membered aryl group or a 6-12 membered heteroaryl group; Y and Z are each independently selected from -CH2-, -S-, -SO-, -SO2-, -(O=S=NH)-, -Se- or -Se(O)-; R 8 , R 11 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl being optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; R 9 , R 10 , R 12 , R 13 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl; R 14 each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more of the following substituents: halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl; EE is selected from -COOH or a carboxyl surrogate; the carboxyl surrogate is selected from: m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; o is 0, 1, 2, 3, 4, or 5; p is 0, 1, 2, 3, 4 or 5; q is 0, 1, 2, or 3.
9. The compound according to claim 8, characterized in that Selected from:
10. Use of the compound according to claim 8 or 9 in the preparation of a GLP-1 receptor agonist, or in the preparation of a medicament for preventing and / or treating diseases associated with GLP-1 receptor stimulation.
